var title_f27_54_28512="Survival by tumor size HCC";
var content_f27_54_28512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Effect of tumor size on survival in patients with a single hepatocellular cancer without vascular invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vauthey, J, Lauwers, GY, Esnaola, NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20:1527. Copyright &copy; 2002 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28512=[""].join("\n");
var outline_f27_54_28512=null;
var title_f27_54_28513="MRI of nerve sheath B";
var content_f27_54_28513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    MRI of lumbar nerve sheath tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    68-year-old male presented with significant biologic pain. Sagittal (a) and axial (b) MRI images showed a cystic lesion at L2 with linear enhancement around the periphery. The tumor was approached via an L2 laminectomy with partial laminectomies at L1 and L3 and intradural exploration. A large motor root, identified with 2 mamp stimulation was identified and dissected off of the tumor capsule. The sensory roots of origin were sharply divided and the tumor was removed en bloc.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28513=[""].join("\n");
var outline_f27_54_28513=null;
var title_f27_54_28514="Pulm bronchogenic cyst CXR";
var content_f27_54_28514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected intrapulmonary cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows cystic lesion in right middle lobe with two gas-liquid levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28514=[""].join("\n");
var outline_f27_54_28514=null;
var title_f27_54_28515="Battery esophageal stenosis";
var content_f27_54_28515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) An esophagram one day after removal of a battery from this child's esophagus shows some subtle narrowing due to tissue damage from the battery. B) A barium swallow two weeks later shows worsening esophageal stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Barbara Specter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28515=[""].join("\n");
var outline_f27_54_28515=null;
var title_f27_54_28516="EUS anorectum";
var content_f27_54_28516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound of the anal sphincter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image demonstrating the internal (IAS) and external (EAS) anal sphincters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28516=[""].join("\n");
var outline_f27_54_28516=null;
var title_f27_54_28517="Cervical cytology: Evaluation of high grade squamous intraepithelial lesions";
var content_f27_54_28517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28517/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/54/28517/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade squamous intraepithelial lesions (HSIL) are the cytologic counterpart to the histologic finding of CIN 2,3, moderate or severe dysplasia, or carcinoma in situ. This topic will review the evaluation of women with HSIL detected during cytological screening for cervical cancer. Evaluation of women with other cervical cytological findings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonpregnant adult women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with HSIL are at high risk of having serious underlying histopathology. When initially evaluated, over 50 percent have CIN 2 or greater and 2 percent have invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. If left untreated, approximately 20 percent of women with biopsy-proven carcinoma in situ will develop an invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/5\">",
"     5",
"    </a>",
"    ]. Therefore, all women (including adolescents) with HSIL should be referred for immediate histological evaluation. Options include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colposcopy of the entire cervix and the vagina fornices (some clinicians evaluate both the upper and lower vagina), with biopsy of all visible lesions and endocervical curettage (ECC). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"       \"Colposcopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immediate loop electrosurgical excision (except in adolescents or pregnant women).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Unsatisfactory colposcopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If colposcopy is unsatisfactory (ie, inability to visualize the entire squamocolumnar junction and entire margins of any lesions), then a diagnostic excisional procedure (loop electrosurgical excision, conization) should be performed to complete the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Satisfactory colposcopy/biopsy confirms CIN 2 or more",
"    </span>",
"    &nbsp;&mdash;&nbsp;If colposcopy is satisfactory and biopsy is confirmatory (ie, CIN 2 or greater), then the patient is treated as appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Satisfactory colposcopy/biopsy shows CIN 1 or less",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single colposcopy can miss a significant number of serious CIN lesions. Given the high prevalence of CIN 2 or greater in women with HSIL, women with a nonconfirmatory colposcopy require further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link&amp;anchor=H15#H15\">",
"     \"Colposcopy\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We feel a cytological diagnosis of HSIL without histologic confirmation of CIN 2 or greater should be managed with a diagnostic excisional procedure in non-adolescent and nonpregnant women because of the significant risk that a high grade lesion has been missed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A diagnostic excisional procedure generally provides adequate tissue for definitive diagnosis. We prefer a loop electrosurgical excision because it can be performed as an office procedure.",
"   </p>",
"   <p>",
"    Another option is to review the cytology smears, colposcopy, and biopsies. In some cases, expert review may result in a change in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In these cases, subsequent management would depend upon the final interpretation.",
"   </p>",
"   <p>",
"    The third option is to closely monitor the patient with both cytology and colposcopy with ECC at six-month intervals for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. If both tests are normal (no intraepithelial neoplasia), then the patient can resume routine screening. If these evaluations are abnormal, then subsequent management depends upon the diagnosis, such as a diagnostic excisional procedure for HSIL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer screening of adolescents (defined as ages 13 to 20 according to the American Society for Colposcopy and Cervical Pathology [ASCCP] guidelines) is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended by the American College of Obstetricians and Gynecologists (ACOG); the only exceptions to this are adolescents infected with human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This recommendation is consistent with guidelines for other professional societies. In the general adolescent patient population, the prevalence of transient HPV infection (and transient cytologic abnormality) is very high while the prevalence of invasive cancer is near zero [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H22#H22\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Initial screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents (ages 13 to 20) with HSIL on cervical cytology should undergo colposcopy with ECC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=see_link\">",
"     \"Consent in adolescent health care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If biopsy of a suspicious lesion reveals CIN 2 or greater, then the patient is managed as appropriate for this population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link&amp;anchor=H22#H22\">",
"     \"Cervical intraepithelial neoplasia: Management\", section on 'Adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If CIN 1 or no lesion is identified, then close observation with both cytology and colposcopy with ECC at six-month intervals for up to two years is warranted, as long as the colposcopy is satisfactory and the ECC is negative.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If two consecutive cytology smears are negative for intraepithelial lesions or malignancy, and colposcopy shows no high-grade abnormality, then routine screening can resume.",
"     </li>",
"     <li>",
"      ASC-US, ASC-H, and LSIL are managed according to standard guidelines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If HSIL cytology persists for 24 months, a diagnostic excisional procedure should be performed. The patient is then managed based upon the results of the biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"       \"Cervical intraepithelial neoplasia: Management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the colposcopy is unsatisfactory or the ECC is positive, the 2006 Bethesda consensus conference recommends a diagnostic excisional procedure. However, we and other experts manage adolescents with an unsatisfactory colposcopy with repeat colposcopy and cervical cytology smear every three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with cytological evidence of HSIL require colposcopy, which is best performed by a colposcopist familiar with the colposcopic changes induced by pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/13\">",
"     13",
"    </a>",
"    ]. Any lesions suspicious for CIN 2 or greater are biopsied, lesser lesions can be sampled at the clinician's discretion, but endocervical curettage should not be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. If the examination is unsatisfactory, repeating the colposcopy after 6 to 12 weeks should allow visualization of the entire squamocolumnar junction.",
"   </p>",
"   <p>",
"    A biopsy suggesting microinvasive or invasive cervical cancer requires consultation with a gynecologic oncologist and maternal-fetal medicine specialist for diagnostic and treatment planning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=see_link\">",
"     \"Cervical cancer in pregnancy\"",
"    </a>",
"    .) We follow CIN 2,3 with colposcopy and cytology examinations at least each trimester, unless the lesion appears to be worsening or cytology suggests invasive cancer, in which case biopsies are performed. Diagnostic excisional procedures are reserved for women in whom invasion is suspected and this knowledge will alter management of the pregnancy or delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Otherwise, if evaluation reveals no CIN 2,3, Bethesda 2006 guidelines recommend re-evaluation with cytology and colposcopy no sooner than six weeks postpartum.",
"   </p>",
"   <p>",
"    We perform postpartum cytologic and colposcopic evaluation on all women with HSIL diagnosed during pregnancy, but defer these examinations until at least six weeks post-delivery to allow the cervix to resume its nonpregnant state.",
"   </p>",
"   <p>",
"    Studies on the natural history of SIL in pregnancy demonstrate that progression to invasive carcinoma during pregnancy is very rare (0 to 0.4 percent) and spontaneous regression of HSIL and CIN 2,3 is common (48 to 70 percent of lesions regress during the course of pregnancy when antepartum and postpartum",
"    <span class=\"nowrap\">",
"     cytology/histology",
"    </span>",
"    are compared) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Whether vaginal delivery is associated with a higher regression rate compared to cesarean delivery remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The importance of a thorough postpartum evaluation was illustrated in a study that identified 28 women with HSIL on a first trimester antepartum cervical cytology smear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28517/abstract/17\">",
"     17",
"    </a>",
"    ]. All were followed with colposcopy and biopsy, as indicated, during pregnancy and at six to eight weeks postpartum. Postpartum, HSIL persisted in 89 percent",
"    <span class=\"nowrap\">",
"     (25/28)",
"    </span>",
"    and microinvasive disease was found in 11 percent",
"    <span class=\"nowrap\">",
"     (3/28).",
"    </span>",
"    Almost all of these women",
"    <span class=\"nowrap\">",
"     (24/28)",
"    </span>",
"    had a history of previous squamous intraepithelial lesions.",
"   </p>",
"   <p>",
"    Mode of delivery is based on usual obstetrical factors; CIN 2,3 is not an indication for cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with high grade intraepithelial lesions (HSIL) are at high risk of having serious underlying histopathology. When initially evaluated, over 50 percent have CIN 2 or greater and 2 percent have invasive cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonpregnant adult women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the high risk of serious histopathology, nonpregnant adult women with HSIL are immediately evaluated by colposcopy with biopsy of all visible lesions and endocervical curettage (ECC) or by a diagnostic excisional procedure. Further management depends upon histological findings. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonpregnant adult women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with HSIL should undergo colposcopy with biopsies of all lesions suspicious of CIN 2,3 or worse. Diagnostic excisional procedures and endocervical curettage are avoided due to the risk of disrupting the pregnancy, unless invasive cancer is suspected. &nbsp;(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/1\">",
"      Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000; 124:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/2\">",
"      Alvarez RD, Wright TC, Optical Detection Group. Effective cervical neoplasia detection with a novel optical detection system: a randomized trial. Gynecol Oncol 2007; 104:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/3\">",
"      Dunn TS, Burke M, Shwayder J. A \"see and treat\" management for high-grade squamous intraepithelial lesion pap smears. J Low Genit Tract Dis 2003; 7:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/4\">",
"      Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol 2001; 82:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/5\">",
"      McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984; 64:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/6\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     www.ASCCP.org (Accessed on April 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/8\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/9\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010; 116:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/10\">",
"      Boardman LA, Stanko C, Weitzen S, Sung CJ. Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol 2005; 105:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/11\">",
"      Sherman ME, Solomon D, Schiffman M, ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol 2001; 116:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/12\">",
"      Wright JD, Pinto AB, Powell MA, et al. Atypical squamous cells of undetermined significance in girls and women. Obstet Gynecol 2004; 103:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/13\">",
"      Economos K, Perez Veridiano N, Delke I, et al. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 1993; 81:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/14\">",
"      Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 1999; 93:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/15\">",
"      Paraskevaidis E, Koliopoulos G, Kalantaridou S, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. Eur J Obstet Gynecol Reprod Biol 2002; 104:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/16\">",
"      Ahdoot D, Van Nostrand KM, Nguyen NJ, et al. The effect of route of delivery on regression of abnormal cervical cytologic findings in the postpartum period. Am J Obstet Gynecol 1998; 178:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28517/abstract/17\">",
"      Kaplan KJ, Dainty LA, Dolinsky B, et al. Prognosis and recurrence risk for patients with cervical squamous intraepithelial lesions diagnosed during pregnancy. Cancer 2004; 102:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3213 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D2AB0E8FD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28517=[""].join("\n");
var outline_f27_54_28517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonpregnant adult women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Unsatisfactory colposcopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Satisfactory colposcopy/biopsy confirms CIN 2 or more",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Satisfactory colposcopy/biopsy shows CIN 1 or less",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_54_28518="Erythema elevatum diutinum - lower extremities";
var content_f27_54_28518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57008%7EDERM%2F67776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57008%7EDERM%2F67776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema elevatum diutinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular lesions are present on the knees in this patient with erythema elevatum diutinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema elevatum diutinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous plaques are present on the extremities in this patient with erythema elevatum diutinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28518=[""].join("\n");
var outline_f27_54_28518=null;
var title_f27_54_28519="Inflammatory mechanisms of lung injury during mechanical ventilation";
var content_f27_54_28519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inflammatory mechanisms of lung injury during mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Arthur S Slutsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28519/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/54/28519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation is a life-saving therapy that has become the mainstay of management for patients with acute respiratory failure. Since its widespread use was initiated in the mid-1950s for the treatment of paralytic poliomyelitis, our understanding of the impact of mechanical ventilation on gas exchange, pulmonary mechanics, and heart-lung interactions in relation to mechanical ventilation has increased tremendously. In addition, the complications of mechanical ventilation have also become more apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse consequences of mechanical ventilation (other than oxygen toxicity) traditionally were thought to be due largely to mechanical factors, such as hemodynamic compromise from decreased venous return",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    barotrauma due to overdistention of the lung. Subsequently, research has revealed more subtle types of ventilator-induced lung injury, including diffuse alveolar damage and up-regulation of the inflammatory response; the latter is referred to as biotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. The concept of biotrauma may help explain why most patients who die with the acute respiratory distress syndrome (ARDS) succumb not because their lungs fail, but because of the development of multiple organ dysfunction syndrome (MODS) involving both the lungs and other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mechanisms of ventilator-induced lung injury, particularly biotrauma, will be reviewed here. General issues related to mechanical ventilation and its use in ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF VENTILATOR-INDUCED LUNG INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barotrauma refers to gross air leaks (including pneumothorax or pneumomediastinum) that are due to the development of an excessive pressure difference between an alveolus and its adjacent bronchovascular sheath [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Factors that impact the development of barotrauma include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The specific diagnosis (more common with ARDS) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"       \"Secondary spontaneous pneumothorax in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Weight loss (malnutrition)",
"     </li>",
"     <li>",
"      Resilience of lung tissue",
"     </li>",
"     <li>",
"      The presence of oxygen toxicity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"       \"Oxygen toxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Overdistention of lung units",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volutrauma refers to a more subtle type of lung injury that can occur secondary to pulmonary over-distention induced by mechanical ventilation. Since this injury was described in 1974, a number of investigators have shown that excessive inspiratory lung stretch can lead to the development of pulmonary edema, diffuse alveolar damage, increased epithelial permeability, and increased microvascular permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The term volutrauma has been applied to this phenomenon, to indicate that the critical variable for injury is not the airway pressure per se, but rather lung volume or end-inspiratory stretch [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyclical atelectasis, also called atelectrauma, refers to the damage that can occur when lungs are allowed to become atelectatic and then are reexpanded [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/19,21-25\">",
"     19,21-25",
"    </a>",
"    ]. Using conventional mechanical ventilation or high frequency oscillation, several studies have shown",
"    <span class=\"nowrap\">",
"     collapse/reexpansion",
"    </span>",
"    to be a critical factor causing injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biotrauma, a response to mechanical stresses described approximately 10 years ago, is characterized by the release of inflammatory mediators from cells within the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/1,2,26\">",
"     1,2,26",
"    </a>",
"    ]. These mediators can cause further injury to lung tissue and to other organ systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOTRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have provided evidence that mechanical ventilation of injured lungs can exacerbate lung injury and lead to an additional inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Although subject to some debate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/28-30\">",
"     28-30",
"    </a>",
"    ] most experimental studies clearly demonstrate that overstretching lung cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allowing",
"    <span class=\"nowrap\">",
"     recruitment/derecruitment",
"    </span>",
"    of the lung can lead to an increase in lung cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/6\">",
"     6",
"    </a>",
"    ]. Under conditions in which there is increased lung permeability, these cytokines may translocate from the alveolar space to the systemic circulation.",
"   </p>",
"   <p>",
"    As an example, conventional ventilation in a rabbit model of lung injury produced severe hypoxemia and pathologic evidence of an influx of large numbers of neutrophils into the lung. This was in marked contrast to the results obtained in animals that were neutrophil-depleted with nitrogen mustard prior to lung lavage, in which the absence of neutrophilic infiltration was associated with an increased PaO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/27\">",
"     27",
"    </a>",
"    ]. These results suggested that mediators released from neutrophils could play a major role in ventilator-induced lung injury. High frequency oscillation in a similar lung lavage model produced a significant decrease in the concentration of inflammatory mediators, including thromboxane B2 and platelet activating factor, when compared to conventional mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=see_link\">",
"     \"High-frequency ventilation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injurious forms of mechanical ventilation can also lead to an increase in cytokine concentrations in previously healthy lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In ex-vivo studies of isolated, non-perfused lungs, strategies that permitted overinflation of the lung (tidal volume of 15",
"    <span class=\"nowrap\">",
"     mL/kg;",
"    </span>",
"    PEEP of 10 cm H20) or those that allowed",
"    <span class=\"nowrap\">",
"     recruitment/de-recruitment",
"    </span>",
"    (tidal volume of 15",
"    <span class=\"nowrap\">",
"     ml/kg,",
"    </span>",
"    PEEP of 0 cm H2O) produced a 3 to 6 fold increase in lung lavage cytokines, including inflammatory and antiinflammatory cytokines, and chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/23\">",
"     23",
"    </a>",
"    ]. When zero PEEP was combined with a strategy using very high end-inspiratory lung volumes, a synergistic effect was observed with a 50 to 60 fold increase in lung lavage TNF-alpha concentrations. The increase in cytokines was associated with an increase in c-fos mRNA, an early response gene, suggesting that the concept of mechano-transduction (the conversion of cell or receptor deformation into biochemical responses) may play an important role in activating intracellular signal transduction pathways and leading to the development of biotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experiments in which isolated lung cells were submitted to cyclic stretch (up to a 7 percent increase in diameter), increasing cell stretch increased release of a number of inflammatory mediators, including TNF-alpha, IL-6, IL-8, and matrix metalloproteinase-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/33\">",
"     33",
"    </a>",
"    ]. The lung macrophage was the main source of these cytokines, which were associated with up-regulation of the transcription factor NF-kB.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    prevented the increase in IL-8, TNF-alpha, and NF-kB [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence that mechanical ventilation may cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsen pulmonary coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]. This is not surprising since there is evidence linking the coagulation and the inflammatory cascades in patients with acute lung injury. Pro-inflammatory cytokines can activate the coagulation system through tissue factor and attenuate the fibrinolytic system by stimulating the release of plasminogen activator inhibitors. In an experimental study, large tidal volume mechanical ventilation attenuated fibrinolytic activity in rats that had fibrinogen and thrombin instilled into their lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study using data collected during a randomized trial found that patients with early acute lung injury had decreased plasma levels of protein C and increased levels of plasminogen activator inhibitor-1, which represented independent risk factors for adverse clinical outcomes and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/40\">",
"     40",
"    </a>",
"    ]. In a smaller study, treatment with activated protein C did not improve outcomes of patients with acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytokines found in the lavage fluid may not be compartmentalized to the lung and may reach the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/43\">",
"     43",
"    </a>",
"    ]. As examples, one isolated perfused mouse model found that ventilation with high end-inspiratory stretch produced an increase in cytokines in the perfusate of the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/32\">",
"     32",
"    </a>",
"    ]. A different group found that application of zero PEEP with a moderately large tidal volume (16",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    in an acid aspiration lung injury model in the rat resulted in an increase in serum TNF-alpha and MIP-2 over a four hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/44\">",
"     44",
"    </a>",
"    ]. When the same tidal volume was used with a higher PEEP level (5 cm H20), there was no significant increase in serum TNF-alpha.",
"   </p>",
"   <p>",
"    These data suggest a mechanism (release of cytokines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory mediators into the systemic circulation) by which mechanical ventilation might affect systemic consequences and lead to the development of end-organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/7,45,46\">",
"     7,45,46",
"    </a>",
"    ]. Further evidence in support of this hypothesis comes from a rabbit acid aspiration model, which demonstrated that an injurious ventilatory strategy induced epithelial cell apoptosis in the kidney, without any demonstrable change in hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/47\">",
"     47",
"    </a>",
"    ]. Using kidney cells in culture researchers went on to suggest that these effects might be mediated by a circulating factor, soluble Fas Ligand (sFasL). Finally, they demonstrated that these results may have relevance in humans: patients with ARDS who were ventilated with a lung protective strategy had lower levels of sFasL than those ventilated using a standard ventilatory approach.",
"   </p>",
"   <p>",
"    There are other mechanisms by which mechanical ventilation could produce systemic consequences by causing translocation of bacteria or endotoxin from the lungs into the systemic circulation. High tidal volume ventilation with zero PEEP of lungs of dogs or rats, into which bacteria had been instilled, led to bacteremia in most of the animals. The addition of PEEP to the ventilation strategy was associated with a markedly lower incidence of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Similarly, a lung protective strategy minimized translocation of endotoxin in a rabbit model in which endotoxin was given intratracheally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clinical data that suggest that biotrauma may be relevant to humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/25\">",
"     25",
"    </a>",
"    ]. In one randomized controlled trial in ARDS patients ventilated with either a conventional ventilatory strategy (tidal volume of 10 to 12",
"    <span class=\"nowrap\">",
"     mL/kg;",
"    </span>",
"    PEEP set at lowest value to maintain adequate oxygenation) or a protective strategy designed to minimize lung stress (PEEP above the lower inflection point; tidal volume such that the plateau pressure was less than the upper inflection point), there was a significant and marked decrease in lavage and serum cytokines in the ventilator group treated with the protective strategy over 36 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decrease in serum cytokines also may explain the decreased mortality observed in a 1998 study in which a high PEEP, low tidal volume (lung protective) strategy resulted in a 40 percent reduction in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/52\">",
"     52",
"    </a>",
"    ]. A similar reduction in mortality in patients with ARDS ventilated with low tidal volumes was announced by the National Heart, Lung, and Blood Institute in 1999, when a study of 861 patients revealed significantly lower mortality (31 versus 40 percent) in patients treated with a low tidal volume strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/8\">",
"     8",
"    </a>",
"    ]. The study protocol compared an initial tidal volume of 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of predicted body weight (and plateau pressure &lt;30 cm H2O) with an initial tidal volume of 12",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    (with plateau pressure &lt;50 cm H2O); attempts were made to standardize PEEP and weaning protocols across both treatment groups. This study also reported a greater decrease in IL-6 in patients treated with the 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    strategy compared to the 12",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subsequent report gave a more detailed analysis of the cytokine profile of these patients. Plasma interleukin-6 and interleukin-8 levels were associated with increased morbidity and mortality, while low tidal volume ventilation was associated with a more rapid attenuation of the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial found that patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/1/26646?source=see_link\">",
"     Cisatracurium",
"    </a>",
"    , a neuromuscular blocking agent, had decreased mortality when given during the first 48 hours following the diagnosis of ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/55\">",
"     55",
"    </a>",
"    ]. It was hypothesized that the decrease was due, in part, to a decrease in ventilator-induced lung injury caused by decreased biotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/56\">",
"     56",
"    </a>",
"    ], since a previous smaller study from the same group had noted a decrease in the inflammatory response in patients with ARDS who were treated with neuromuscular blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/57\">",
"     57",
"    </a>",
"    ]. This is consistent with the observation that the decrease in mortality between the two groups did not start until about day 16 of the trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most direct approach to minimize lung injury is to utilize a protective ventilatory strategy. However, in many patients with severe ARDS, this may not be possible because of the gross spatial heterogeneity in pathology and lung mechanics in these patients. The lungs in patients with ARDS can be thought of as consisting of three zones: collapsed lung regions, lung regions that are open to recruitment, and over-distended regions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Thus, a ventilatory strategy that may be protective for one region of the lung may be injurious for a neighboring region.",
"   </p>",
"   <p>",
"    Consequently, future therapy may be aimed at mitigating biotrauma by the use of anti-inflammatory agents, antibodies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gene transfer approaches. Early examples of these approaches that have shown promise in animal models include the use of an agent to effect interleukin (IL)-1b blockade or intratracheal instillation of antibodies to tumor necrosis factor (TNF)-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach to mitigate biotrauma due to ventilator-induced lung injury is to get rid of the ventilator, or at least markedly decrease the stresses induced by mechanical ventilation. One such approach is the use of extracorporeal approaches to achieve gas exchange. One study used extracorporeal carbon dioxide removal, along with decreased tidal volumes and lower plateau pressures in patients with ARDS, and found lower cytokine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28519/abstract/62\">",
"     62",
"    </a>",
"    ]. The study was too small to look at important clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical ventilation can worsen preexisting lung injury or even cause injury to previously healthy lungs units. Traditional thinking about ventilator-induced lung injury has focused upon the direct mechanical consequences of ventilation; however, there is now evidence of a more subtle and potentially more lethal mechanism of ventilator-induced lung injury called biotrauma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of ventilator-induced lung injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The concept of biotrauma has mechanistic and clinical implications (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Biotrauma'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      First, it suggests a novel mechanism of disease. Although the initial inciting event during ventilator-induced lung injury may be mechanical in nature, it may trigger a complex cascade of events that culminate in the release of inflammatory mediators.",
"     </li>",
"     <li>",
"      Second, these results may explain the observation that many patients with acute respiratory distress syndrome (ARDS) die from multiple organ dysfunction syndrome (MODS), not hypoxemia. Biotrauma may be the missing link between the pulmonary pathophysiology of ARDS and the pathobiology of MODS, which is common in this disease.",
"     </li>",
"     <li>",
"      Finally, these concepts may lead to a paradigm shift in which novel therapy of ventilator-induced lung injury is based not only upon minimizing the physical forces causing injury, but also on modulating biotrauma using anti-inflammatory or anti-apoptotic interventions to help limit the extent and extrapulmonary consequences of ventilator-induced inflammation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical implications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/1\">",
"      Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006; 32:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/2\">",
"      Tremblay LN, Slutsky AS. Ventilator-induced injury: from barotrauma to biotrauma. Proc Assoc Am Physicians 1998; 110:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/3\">",
"      Pl&ouml;tz FB, Slutsky AS, van Vught AJ, Heijnen CJ. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. Intensive Care Med 2004; 30:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/4\">",
"      Lionetti V, Recchia FA, Ranieri VM. Overview of ventilator-induced lung injury mechanisms. Curr Opin Crit Care 2005; 11:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/5\">",
"      dos Santos CC, Slutsky AS. The contribution of biophysical lung injury to the development of biotrauma. Annu Rev Physiol 2006; 68:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/6\">",
"      Halbertsma FJ, Vaneker M, Scheffer GJ, van der Hoeven JG. Cytokines and biotrauma in ventilator-induced lung injury: a critical review of the literature. Neth J Med 2005; 63:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/7\">",
"      Slutsky AS, Tremblay LN. Multiple system organ failure. Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med 1998; 157:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/8\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/9\">",
"      Macklin, CC. Transport of air along sheaths of pulmonic blood vessels from alveoli to mediastinum. Arch Intern Med 1939; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/10\">",
"      Rouby JJ, Lherm T, Martin de Lassale E, et al. Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure. Intensive Care Med 1993; 19:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/11\">",
"      Pierson, DJ. Alveolar rupture during mechanical ventilation: role of PEEP, peak airway pressure, and distending volume. Respir Care 1988; 33:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/12\">",
"      Gammon RB, Shin MS, Groves RH Jr, et al. Clinical risk factors for pulmonary barotrauma: a multivariate analysis. Am J Respir Crit Care Med 1995; 152:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/13\">",
"      Webb HH, Tierney DF. Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures. Protection by positive end-expiratory pressure. Am Rev Respir Dis 1974; 110:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/14\">",
"      Parker JC, Hernandez LA, Longenecker GL, et al. Lung edema caused by high peak inspiratory pressures in dogs. Role of increased microvascular filtration pressure and permeability. Am Rev Respir Dis 1990; 142:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/15\">",
"      Parker JC, Hernandez LA, Peevy KJ. Mechanisms of ventilator-induced lung injury. Crit Care Med 1993; 21:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/16\">",
"      Dreyfuss D, Saumon G. Barotrauma is volutrauma, but which volume is the one responsible? Intensive Care Med 1992; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/17\">",
"      Dreyfuss D, Saumon G. Role of tidal volume, FRC, and end-inspiratory volume in the development of pulmonary edema following mechanical ventilation. Am Rev Respir Dis 1993; 148:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/18\">",
"      Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 1998; 157:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/19\">",
"      Slutsky AS. Lung injury caused by mechanical ventilation. Chest 1999; 116:9S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/20\">",
"      Vlahakis NE, Hubmayr RD. Cellular stress failure in ventilator-injured lungs. Am J Respir Crit Care Med 2005; 171:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/21\">",
"      Chu EK, Whitehead T, Slutsky AS. Effects of cyclic opening and closing at low- and high-volume ventilation on bronchoalveolar lavage cytokines. Crit Care Med 2004; 32:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/22\">",
"      Sandhar BK, Niblett DJ, Argiras EP, et al. Effects of positive end-expiratory pressure on hyaline membrane formation in a rabbit model of the neonatal respiratory distress syndrome. Intensive Care Med 1988; 14:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/23\">",
"      Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med 1994; 149:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/24\">",
"      Hamilton PP, Onayemi A, Smyth JA, et al. Comparison of conventional and high-frequency ventilation: oxygenation and lung pathology. J Appl Physiol 1983; 55:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/25\">",
"      Lachmann B. Open up the lung and keep the lung open. Intensive Care Med 1992; 18:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/26\">",
"      Imai Y, Kawano T, Miyasaka K, et al. Inflammatory chemical mediators during conventional ventilation and during high frequency oscillatory ventilation. Am J Respir Crit Care Med 1994; 150:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/27\">",
"      Kawano T, Mori S, Cybulsky M, et al. Effect of granulocyte depletion in a ventilated surfactant-depleted lung. J Appl Physiol 1987; 62:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/28\">",
"      Ricard JD, Dreyfuss D, Saumon G. Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal. Am J Respir Crit Care Med 2001; 163:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/29\">",
"      Uhlig S, Ranieri M, Slutsky AS. Biotrauma hypothesis of ventilator-induced lung injury. Am J Respir Crit Care Med 2004; 169:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/30\">",
"      Hubmayr RD. Ventilator-induced lung injury without biotrauma? J Appl Physiol 2005; 99:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/31\">",
"      Tremblay L, Valenza F, Ribeiro SP, et al. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/32\">",
"      von Bethmann AN, Brasch F, N&uuml;sing R, et al. Hyperventilation induces release of cytokines from perfused mouse lung. Am J Respir Crit Care Med 1998; 157:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/33\">",
"      Pugin J, Dunn I, Jolliet P, et al. Activation of human macrophages by mechanical ventilation in vitro. Am J Physiol 1998; 275:L1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/34\">",
"      Held HD, Boettcher S, Hamann L, Uhlig S. Ventilation-induced chemokine and cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids. Am J Respir Crit Care Med 2001; 163:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/35\">",
"      Dahlem P, Bos AP, Haitsma JJ, et al. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 2005; 31:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/36\">",
"      Dahlem P, Bos AP, Haitsma JJ, et al. Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J 2006; 28:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/37\">",
"      Choi G, Wolthuis EK, Bresser P, et al. Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 2006; 105:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/38\">",
"      Haitsma JJ, Schultz MJ, Hofstra JJ, et al. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Eur Respir J 2008; 32:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/39\">",
"      Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review. Crit Care Med 2006; 34:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/40\">",
"      Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/41\">",
"      Hofstra JJ, Haitsma JJ, Juffermans NP, et al. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 2008; 34:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/42\">",
"      Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/43\">",
"      Tutor JD, Mason CM, Dobard E, et al. Loss of compartmentalization of alveolar tumor necrosis factor after lung injury. Am J Respir Crit Care Med 1994; 149:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/44\">",
"      Chiumello D, Pristine G, Slutsky AS. Mechanical ventilation affects local and systemic cytokines in an animal model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/45\">",
"      Borrelli E, Roux-Lombard P, Grau GE, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996; 24:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/46\">",
"      Law MM, Cryer HG, Abraham E. Elevated levels of soluble ICAM-1 correlate with the development of multiple organ failure in severely injured trauma patients. J Trauma 1994; 37:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/47\">",
"      Imai Y, Parodo J, Kajikawa O, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 2003; 289:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/48\">",
"      Nahum A, Hoyt J, Schmitz L, et al. Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med 1997; 25:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/49\">",
"      Verbrugge SJ, Sorm V, van 't Veen A, et al. Lung overinflation without positive end-expiratory pressure promotes bacteremia after experimental Klebsiella pneumoniae inoculation. Intensive Care Med 1998; 24:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/50\">",
"      Murphy DB, Cregg N, Tremblay L, et al. Adverse ventilatory strategy causes pulmonary-to-systemic translocation of endotoxin. Am J Respir Crit Care Med 2000; 162:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/51\">",
"      Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999; 282:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/52\">",
"      Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/53\">",
"      Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/54\">",
"      Parsons PE, Matthay MA, Ware LB, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288:L426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/55\">",
"      Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/56\">",
"      Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med 2010; 363:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/57\">",
"      Forel JM, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006; 34:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/58\">",
"      Victorino JA, Borges JB, Okamoto VN, et al. Imbalances in regional lung ventilation: a validation study on electrical impedance tomography. Am J Respir Crit Care Med 2004; 169:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/59\">",
"      Gattinoni L, D'Andrea L, Pelosi P, et al. Regional effects and mechanism of positive end-expiratory pressure in early adult respiratory distress syndrome. JAMA 1993; 269:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/60\">",
"      Narimanbekov IO, Rozycki HJ. Effect of IL-1 blockade on inflammatory manifestations of acute ventilator-induced lung injury in a rabbit model. Exp Lung Res 1995; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/61\">",
"      Imai Y, Kawano T, Iwamoto S, et al. Intratracheal anti-tumor necrosis factor-alpha antibody attenuates ventilator-induced lung injury in rabbits. J Appl Physiol 1999; 87:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28519/abstract/62\">",
"      Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology 2009; 111:826.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1620 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28519=[""].join("\n");
var outline_f27_54_28519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF VENTILATOR-INDUCED LUNG INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOTRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=related_link\">",
"      High-frequency ventilation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_54_28520="Measurement and clinical significance of antinuclear antibodies";
var content_f27_54_28520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measurement and clinical significance of antinuclear antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Morris Reichlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28520/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/54/28520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 14, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies (ANAs) were initially discovered in the 1940s using the lupus erythematosus (LE) cell test. The autoantibodies promoted phagocytosis of nuclei of disrupted cells by leukocytes (",
"    <a class=\"graphic graphic_picture graphicRef62681 \" href=\"UTD.htm?41/12/42191\">",
"     picture 1",
"    </a>",
"    ). The LE cell (a phagocyte with an ingested nucleus) may be an incidental finding in pleural, pericardial, or peritoneal fluids from patients with ANAs and may be a valuable clue to the presence of these autoantibodies. However, ordering of an \"LE cell test\" has generally been replaced by testing of serum for ANAs.",
"   </p>",
"   <p>",
"    ANAs are serologic hallmarks of patients with systemic autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/1\">",
"     1",
"    </a>",
"    ]. These antibodies can also provide further diagnostic and prognostic data concerning patients who have minimal symptoms or who have clinical features of more than one autoimmune disease.",
"   </p>",
"   <p>",
"    Thus, the usefulness of testing for ANAs is in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To help establish a diagnosis in a patient with clinical features suggestive of an autoimmune or connective tissue disorder",
"     </li>",
"     <li>",
"      To exclude such disorders in patients with few or uncertain clinical findings",
"     </li>",
"     <li>",
"      To subclassify a patient with an established diagnosis of an autoimmune or connective tissue disease",
"     </li>",
"     <li>",
"      To monitor disease activity (eg, anti-double stranded DNA antibody levels in lupus nephritis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the clinical utility of ANAs. The clinical manifestations, diagnosis, and treatment of the diseases associated with these antibodies are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASES ASSOCIATED WITH A POSITIVE ANA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive ANA can be seen with systemic autoimmune diseases, organ-specific autoimmune diseases, and a variety of infections. Their presence does not mandate the presence of illness, since they can also be found in otherwise normal individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Systemic autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive ANA is an essential component of the definition of some systemic autoimmune disorders, such as systemic lupus erythematosus (SLE), but can also be found in association with many autoimmune disorders that are not defined by these antibodies. As a result, the sensitivity of a positive ANA for a particular autoimmune disease can vary widely (",
"    <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"UTD.htm?38/63/39934\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SLE &mdash; 93 percent",
"     </li>",
"     <li>",
"      Scleroderma &mdash; 85 percent",
"     </li>",
"     <li>",
"      Mixed connective tissue disease &mdash; 93 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Polymyositis/dermatomyositis",
"      </span>",
"      &mdash; 61 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rheumatoid arthritis &mdash; 41 percent",
"     </li>",
"     <li>",
"      Rheumatoid vasculitis &mdash; 33 percent",
"     </li>",
"     <li>",
"      Sj&ouml;gren's syndrome &mdash; 48 percent",
"     </li>",
"     <li>",
"      Drug-induced lupus &mdash;100 percent",
"     </li>",
"     <li>",
"      Discoid lupus &mdash; 15 percent",
"     </li>",
"     <li>",
"      Pauciarticular juvenile chronic arthritis &mdash; 71 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific organ autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive ANAs are occasionally seen in patients with autoimmune diseases that are limited to a specific organ such as the thyroid gland, liver, or lung. The following sensitivities have been reported in these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hashimoto's thyroiditis &mdash; 46 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Graves' disease &mdash; 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoimmune hepatitis &mdash; 63 to 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis 10 to 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Primary autoimmune cholangitis &mdash; 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Idiopathic pulmonary arterial hypertension &mdash; 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other well-recognized disorders associated with a positive ANA titer include chronic infectious diseases, such as mononucleosis, hepatitis C infection, subacute bacterial endocarditis, tuberculosis, and human immunodeficiency virus (HIV), and some lymphoproliferative diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. The presence of ANAs is rarely associated with malignancy, with the exception of dermatomyositis in which both may be present. ANAs have also been identified in up to 50 percent of patients taking certain drugs; however, most of these patients do not develop drug-induced lupus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    False positive ANAs (ie, ANAs in the absence of autoimmune disease or known antigenic stimuli) are more commonly seen in women and in elderly patients. The majority of these are present in low titer (see",
"    <a class=\"local\" href=\"#H16\">",
"     'False positives'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPES OF ANTINUCLEAR ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different types of ANAs are defined by their target antigen, including double stranded DNA, individual nuclear histones, other nuclear proteins, and RNA-protein complexes. As will be seen, some of these antibodies are relatively specific for a particular disease (",
"    <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"UTD.htm?38/63/39934\">",
"     table 1A-B",
"    </a>",
"    ) or for specific clinical manifestations in patients with SLE (",
"    <a class=\"graphic graphic_table graphicRef72522 \" href=\"UTD.htm?22/28/22988\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibodies to double-stranded DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to high titers of antibodies directed against double-stranded (native) DNA are very specific for SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    .) Serial measurement of anti-double stranded DNA is used by some as an aid to monitoring the activity of lupus nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibodies that react with single stranded (denatured) DNA but not with double-stranded DNA while frequently detected in SLE sera are not specific for this disease and have been reported after exposure to drugs and in patients with other connective tissue diseases including rheumatoid arthritis. While older methods of detecting anti-double stranded DNA antibodies employed DNA contaminated with single-stranded DNA, commercially available assays are currently relatively free of these antigenic fragments.",
"   </p>",
"   <p>",
"    The tumor necrosis factor alpha inhibitors, which are used in the treatment of rheumatoid arthritis and other disorders, can induce the production of anti-double stranded DNA antibodies in a small proportion of patients. Most of these patients who develop antibodies have not manifested clinical features of SLE, although the duration of follow up has been relatively short [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link&amp;anchor=H13#H13\">",
"     \"Infliximab in Crohn's disease\", section on 'Patients with fistulizing disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibodies to individual histones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seventy percent of patients with SLE have ANAs that recognize individual nuclear histones and they tend to make antibodies to H1 and H2B histones. In contrast, patients with drug-induced lupus tend to make antibodies to H2A-H2B or H3-H4 histones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .) In one study of 394 patients with rheumatic diseases, antibodies to H1 histone had a sensitivity of 45 percent and a specificity for SLE of over 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/20\">",
"     20",
"    </a>",
"    ]. A Th1 cellular immune response to histone H1 has also been observed in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with drug-induced lupus due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    most commonly do not have antibodies directed against nonhistone nuclear antigens, a serological feature often used to distinguish between drug-induced and idiopathic SLE (",
"    <a class=\"graphic graphic_table graphicRef69467 \" href=\"UTD.htm?14/62/15341\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibodies to chromatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromatin refers to the complex of histones and DNA. Antibodies to the H2A-H2B-DNA (nucleosome) complex constitute anti-chromatin antibodies. Assaying for the presence of anti-chromatin (anti-nucleosome) antibodies may be more clinically relevant than testing for individual anti-histone antibodies. This was illustrated in a study of 100 patients with SLE and other connective tissue disease controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/22\">",
"     22",
"    </a>",
"    ]. Anti-chromatin antibodies were present in 69 percent of those with SLE but in 10 percent or less of patients with Sj&ouml;gren's syndrome, scleroderma, or antiphospholipid syndrome. Among those with SLE, the prevalence of anti-chromatin antibodies was two fold higher in those with renal disease (58 percent versus 29 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=see_link&amp;anchor=H2#H2\">",
"     \"Miscellaneous antinuclear antibodies\", section on 'Nucleosome (chromatin)-specific autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibodies to other nuclear proteins and RNA-protein complexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against nuclear proteins and ribonucleoprotein (RNP) complexes are associated with the following autoimmune disorders (",
"    <a class=\"graphic graphic_table graphicRef72522 \" href=\"UTD.htm?22/28/22988\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to U1-RNP are associated with mixed connective tissue disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"       \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"      </a>",
"      .) They have been found in a small proportion (2 of 70) of patients with localized (linear) scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/25\">",
"       25",
"      </a>",
"      ]. They are present in about 30 to 40 percent of patients with SLE and usually are found in conjunction with antibodies to the Smith antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibody to the Smith (Sm) antigen is very specific for SLE, but only occurs in 25 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/26\">",
"       26",
"      </a>",
"      ]. The reported prevalence of anti-Sm antibodies in SLE varies with the method of detection and the ethnicity of the patient population tested [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/27\">",
"       27",
"      </a>",
"      ]. As an example, among 150 French patients with SLE the prevalence of anti-Sm was five-fold higher in those of French West Indian ancestry than \"mainland\" patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"       \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       La/SSB",
"      </span>",
"      antibodies have been detected in high frequency in the serum of patients with Sj&ouml;gren's syndrome, and subacute cutaneous LE [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. They are also associated with neonatal LE [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Their prevalence in SLE in general is approximately 40 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"       \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies to topoisomerase I (Scl-70), proteins associated with the centromere (CEN-A, CEN-B, etc), U3-ribonucleoprotein (U-3 RNP), RNA polymerases I and III are associated with systemic sclerosis (scleroderma) related disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\", section on 'Laboratory tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antinucleolar specificity is due to a variety of antibodies, including those that bind to",
"      <span class=\"nowrap\">",
"       Th/To,",
"      </span>",
"      ribonuclease complexes (eg, MRP and RNase P), nucleophosphoprotein, fibrillarin, MPP10, and hU3-55; these antinucleolar antibodies are associated primarily with systemic sclerosis (scleroderma, SSc). They are present in approximately 20 percent of patients with SSc [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\", section on 'Laboratory tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies to nuclear pore proteins. These include antibodies to the gp210 and p62 proteins of the nuclear pore complex that are found in 10 to 40 percent of patients with primary biliary cirrhosis and are very specific for this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/34\">",
"       34",
"      </a>",
"      ]. Antibodies to lamin appear to be associated with the presence of antiphospholipid antibodies (aPL). However, having both anti-lamin antibodies and aPL is associated with a lower risk of thrombosis than is the presence of aPL alone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PERFORMANCE OF THE ANA ASSAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The titer and specificity of antinuclear antibodies vary depending upon the antigen substrate used for the assay. Most laboratories currently use HEp2 cells (Human epithelial cell tumor line), which provide certain advantages over the frozen sections of murine organs previously used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. HEp2 cells offer a standardized substrate with larger nuclei and nucleoli. They also provide better sensitivity for antibodies to nuclear antigens present during cell division, such as the centromere antigens. In addition, ANA titers are almost always higher when measured on HEp2 cells when compared to tissue sections of murine liver or kidney. One study, for example, found that the ANA titer was higher when measured on HEp2 cells than on rat livers in 78 of 79 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the shortcomings of the traditional Hep2 cell ANA assay was the low concentration of",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    antigen in the nuclei of these cells. Sera primarily reactive with this antigen might be interpreted as negative. Many laboratories now employ Hep2 cells transfected with the gene for Ro, which have an increased reactivity with",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies.",
"   </p>",
"   <p>",
"    The assay is performed by first incubating HEp2 cells that have been fixed with methanol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acetone with a patient's serum, and then overlaying this combination with fluorochrome labeled anti-human gamma globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/37\">",
"     37",
"    </a>",
"    ]. When viewed through the fluorescent microscope, antibodies bound to nuclear antigens produce a nuclear pattern. The pattern of fluorescence and the dilution at which nuclear fluorescence disappears (titer) are subsequently noted. Differences in titer of one tube dilution commonly occur, but are without clinical significance. Certain antibody specificities, such as anticentromere, can be read directly from the ANA.",
"   </p>",
"   <p>",
"    However, further testing must be performed for other antibody determinations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-Sm, RNP, Ro (SSA), La (SSB), Scl-70, CENP, and Jo-1 antibodies are detected by immunoblotting, ELISA, and occasionally immunodiffusion.",
"     </li>",
"     <li>",
"      Antibodies to dsDNA may be measured by immunoblotting, ELISA, immunofluorescence, or radioimmunoassay, though commercially available assays using the latter technique are not widely available.",
"     </li>",
"     <li>",
"      Antibodies to histones are generally detected by ELISA, immunoblotting, or Western blotting.",
"     </li>",
"     <li>",
"      Antibodies to chromatin are detected by ELISA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, the tremendous interlaboratory variability of ANA results led to a great deal of confusion. The ANA is presently reliable and reproducible, since most laboratories use commercially available tissue culture cell substrates and participate in proficiency testing. The ability to accurately perform an ANA assay is extremely important. This test is currently the cornerstone of the laboratory investigation of systemic connective tissue disease and, quite often, is of critical diagnostic significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enzyme linked immunosorbent assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are ongoing attempts to substitute the enzyme linked immunosorbent assay (ELISA) for the immunofluorescence ANA assay, the current gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. The advantage of an ELISA over the immunofluorescence ANA assay is the ability to automate the procedure. Antigenic substrates for the ELISA have consisted of extracts of nuclei, recombinant antigens, or purified antigens.",
"   </p>",
"   <p>",
"    There are a number of commercial sources of ELISA-ANA testing. Each kit relies upon a different method for preparing and coating the nuclear antigens on the microtiter wells. With at least one of the kits (Bio-Rad), there was an excellent correlation between positivity with the ELISA test and significant titers by immunofluorescence.",
"   </p>",
"   <p>",
"    Because the ELISA method can be automated and is much less labor intensive, many commercial laboratories are now screening antinuclear antibody tests by ELISA and then assaying for ANA titer only the ELISA-positive specimens. The reliability of the ELISA assay that employ recombinant nuclear antigens may not be as reliable as other methods, at least when detecting antinuclear antibodies in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/40\">",
"     40",
"    </a>",
"    ]. Furthermore, we and others feel that this method is inferior to the gold standard, the immunofluorescent system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/39,41-43\">",
"     39,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nuclear staining patterns can result from antibodies directed against different nuclear antigens. The accurate interpretation of these patterns requires considerable experience, and evaluation of the patient. When used properly, an accurate ANA with titer, in combination with a full history and physical examination, can be extremely useful in the diagnosis and exclusion of connective tissue disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Types and usefulness of staining pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies produce a wide range of different staining patterns that reflect the presence of antibodies to one or a combination of nuclear antigens. Although the nuclear staining pattern was commonly used in the past to detect specific antibody and antigen specificity (",
"    <a class=\"graphic graphic_picture graphicRef53431 \" href=\"UTD.htm?42/13/43224\">",
"     picture 2",
"    </a>",
"    ), the pattern type has been recognized to have a relatively low sensitivity and specificity for different autoimmune disorders. At present, specific tests have largely supplanted the use of patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/31,32,44\">",
"     31,32,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The homogeneous or diffuse pattern represents antibodies to the DNA-histone complex, also called deoxyribonucleoprotein or nucleosome. It is believed that these antibodies are responsible for the LE phenomenon.",
"     </li>",
"     <li>",
"      The peripheral or rim pattern is produced by antibodies to DNA and antibodies to nuclear envelope antigens, particularly to lamins [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The speckled pattern is produced by antibodies to Sm, RNP,",
"      <span class=\"nowrap\">",
"       Ro/SSA,",
"      </span>",
"      <span class=\"nowrap\">",
"       La/SSB,",
"      </span>",
"      Scl-70, centromere, proliferating cell nuclear antigen (PCNA), and other antigens.",
"     </li>",
"     <li>",
"      The nucleolar pattern is produced by antibodies to RNA polymerase I, proteins of the small nucleolar RNP complex (fibrillarin, Mpp10, and hU3-55K),",
"      <span class=\"nowrap\">",
"       Th/To,",
"      </span>",
"      B23, PM-Scl, and NOR-90, and other antigens.",
"     </li>",
"     <li>",
"      The centromeric pattern is produced by antibodies to proteins that are associated with the site of chromosomal constriction. Proteins designated: CENP-A, CENP-B, CENP-C, etc, are only present on active centromeres (ie, during meiosis and mitosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these general observations, it is increasingly clear that accurate interpretation of different nuclear patterns is confounded by the following difficulties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The recognition of specific patterns is operator-dependent, and does not produce a permanent record.",
"     </li>",
"     <li>",
"      Different serum dilutions can produce varying nuclear patterns.",
"     </li>",
"     <li>",
"      One nuclear pattern may obscure and prevent the recognition of another pattern if several antibodies are present simultaneously.",
"     </li>",
"     <li>",
"      Certain specificities are visible only on specific substrates. Anti-Ro antibodies and anticentromere antibodies, for example, are not easily detected with murine organs, but can be found with dividing HEp2 cells.",
"     </li>",
"     <li>",
"      Nuclear patterns are neither sensitive nor specific. As a result, no single pattern denotes a single disease and, conversely, several diseases may produce a particular ANA pattern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to these difficulties, specific nuclear pattern recognition is not as useful as previously thought. Pattern recognition has been increasingly supplanted by assays that detect specific antibodies to an ever-increasing array of nuclear antigens and to antigens not normally found in the nucleus (eg, Jo-1 in",
"    <span class=\"nowrap\">",
"     dermatomyositis/polymyositis",
"    </span>",
"    and the ribosomal P proteins in some forms of central nervous system involvement in SLE).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Usefulness of ANA titer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike nuclear pattern recognition, the determination of the titer of antinuclear antibodies still provides clinically relevant information. As an example, a patient with no objective clinical evidence of an autoimmune disorder but with an extremely high ANA titer should be followed expectantly for the emergence of a possible illness. However, ANA titers are less helpful or important in patients with unmistakable clinical evidence of a systemic connective tissue disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of very high concentrations of antibody (titer &gt;1:640) should arouse suspicion of an autoimmune disorder. However, its presence alone is not diagnostic of disease. If no initial diagnosis can be made, it is our practice to watch the patient carefully over time and to exclude ANA associated diseases.",
"     </li>",
"     <li>",
"      The combination of very low titers of antibody (&lt;1:80) and no signs or symptoms of disease portend a much less ominous prognosis. As a result, these patients need to be reevaluated far less frequently than those with extremely high antibody titers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     False positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive ANAs are commonly found in the normal population. When HEp2 cells are used as a substrate, one study of 125 normal individuals found an ANA titer above 1:40 in 32 percent, above 1:80 in 13 percent, and above 1:320 in three percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/16\">",
"     16",
"    </a>",
"    ]. No patient had anti-double stranded DNA antibodies.",
"   </p>",
"   <p>",
"    Antibody titers in healthy individuals usually remain relatively constant over time, a finding that can also be seen in patients with known disease.",
"   </p>",
"   <p>",
"    We feel strongly that the very low specificity of a positive ANA in the absence of clinical findings of an autoimmune disorder",
"    <strong>",
"     precludes",
"    </strong>",
"    its use as a screening test for disease in the general healthy population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     False negatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain antinuclear antibodies can be detected at high titer using certain methods and techniques, but are only found at low titer or may even be absent when assayed using other techniques. These confounding findings result from a number of technical and physical nuances, including the method of substrate fixation, the solubility of the antigen (eg, Ro, La, PCNA, and Ku), and the localization of the antigen outside the nucleus (ie, Jo-1 and single stranded DNA). Due to this limitation, a patient with a negative ANA and strong clinical evidence of a systemic autoimmune disorder may require specific antibody assays to accurately diagnose a rheumatic disease. However, there is rarely any need to request testing for antibodies to DNA, Sm, RNP,",
"    <span class=\"nowrap\">",
"     Ro/SSa,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     La/SSb",
"    </span>",
"    unless the ANA is known to be positive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28520/abstract/2,47\">",
"     2,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=see_link\">",
"       \"Patient information: Antinuclear antibodies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/61/13265?source=see_link\">",
"       \"Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies (ANA) are serologic hallmarks of patients with systemic autoimmune disease. These antibodies can help establish a diagnosis in a patient with clinical features suggestive of an autoimmune or connective tissue disorder, exclude such disorders in patients with few or uncertain clinical findings, subclassify patients with an established diagnosis, and be used to monitor disease activity. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive ANA can be seen with systemic autoimmune diseases, organ-specific autoimmune diseases, and a variety of infections. Their presence does not mandate the presence of illness, since they can also be found in otherwise normal individuals. The sensitivity of a positive ANA for a particular autoimmune disease can vary widely. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diseases associated with a positive ANA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The different types of ANAs are defined by their target antigen, including double-stranded DNA, individual nuclear histones, other nuclear proteins, and RNA-protein complexes. Some of these antibodies are relatively specific for a particular disease or for specific clinical manifestations in patients with SLE. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Types of antinuclear antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The titer and specificity of antinuclear antibodies vary depending upon the antigen substrate used for the assay. Most laboratories currently use HEp2 cells (Human epithelial cell tumor line), for indirect immunofluorescence assays. Other commonly used techniques for detection of specific ANA include enzyme linked immunosorbent assays (ELISA), immunoblotting, and occasionally immunodiffusion or Western blotting. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Performance of the ANA assay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immunofluorescence ANA assay is the current \"gold standard.\" However, many laboratories are now screening antinuclear antibody tests by ELISA because the ELISA method can be automated and is much less labor intensive. The reliability of the ELISA assays that employ recombinant nuclear antigens may be less than other methods and inferior to the immunofluorescence system. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Performance of the ANA assay'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Enzyme linked immunosorbent assay'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The interpretation of the ANA titer and staining pattern requires consideration of the clinical context. The pattern type has been found to have relatively low sensitivity and specificity for different autoimmune disorders, and tests for specific antibodies have largely supplanted the use of patterns. Unlike nuclear pattern recognition, the titer of antinuclear antibodies provides clinically relevant information. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interpretation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Types and usefulness of staining pattern'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Usefulness of ANA titer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positive ANAs are commonly found in the normal population, and the very low specificity of a positive ANA in the absence of clinical findings of an autoimmune disorder precludes its use as a screening test for disease in the general healthy population. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'False positives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient with a negative ANA and strong clinical evidence of a systemic autoimmune disorder may require specific antibody assays to accurately diagnose a rheumatic disease, due to the limitation of particular techniques to detect specific antibodies that may be present. However, there is rarely any need to request testing for antibodies to DNA, Sm, RNP,",
"      <span class=\"nowrap\">",
"       Ro/SSa,",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       La/SSb",
"      </span>",
"      unless the ANA is known to be positive. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'False negatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Reichlin M. Diagnosis criteria and serology. In: Clinical Management of Systemic Lupus Erythematosus, Schur PH (Ed), Grune and Stratton, New York 1983. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/2\">",
"      Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol 2002; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/3\">",
"      Reichlin M, Arnett FC Jr. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/4\">",
"      Rosenberg AM. The clinical associations of antinuclear antibodies in juvenile rheumatoid arthritis. Clin Immunol Immunopathol 1988; 49:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/5\">",
"      Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/6\">",
"      Petri M, Karlson EW, Cooper DS, Ladenson PW. Autoantibody tests in autoimmune thyroid disease: a case-control study. J Rheumatol 1991; 18:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/7\">",
"      Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/8\">",
"      Dagenais A, Bibor-Hardy V, Sen&eacute;cal JL. A novel autoantibody causing a peripheral fluorescent antinuclear antibody pattern is specific for nuclear pore complexes. Arthritis Rheum 1988; 31:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/9\">",
"      Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/10\">",
"      Rich S, Kieras K, Hart K, et al. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/11\">",
"      Kaplan ME, Tan EM. Antinuclear antibodies in infectious mononucleosis. Lancet 1968; 1:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/12\">",
"      Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/13\">",
"      Bonnet F, Pineau JJ, Taupin JL, et al. Prevalence of cryoglobulinemia and serological markers of autoimmunity in human immunodeficiency virus infected individuals: a cross-sectional study of 97 patients. J Rheumatol 2003; 30:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/14\">",
"      Burnham TK. Antinuclear antibodies in patients with malignancies. Lancet 1972; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/15\">",
"      Seiner M, Klein E, Klein G. Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases. Clin Immunol Immunopathol 1975; 4:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/16\">",
"      Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in \"healthy\" individuals. Arthritis Rheum 1997; 40:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/17\">",
"      Guyomard S, Salles G, Coudurier M, et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol 2003; 123:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/18\">",
"      Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/19\">",
"      Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/20\">",
"      Schett G, Smole J, Zimmermann C, et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 2002; 11:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/21\">",
"      Stummvoll GH, Fritsch RD, Meyer B, et al. Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus. Ann Rheum Dis 2009; 68:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/22\">",
"      Cervera R, Vi&ntilde;as O, Ramos-Casals M, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/23\">",
"      Tokano Y, Yasuma M, Harada S, et al. Clinical significance of IgG subclasses of Anti-Sm and U1 ribonucleoprotein antibodies in patients with systemic lupus erythematosus and mixed connective tissue disease. J Clin Immunol 1991; 11:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/24\">",
"      Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991; 18:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/25\">",
"      Yamane K, Ihn H, Kubo M, et al. Anti-U1RNP antibodies in patients with localized scieroderma. Arch Dermatol Res 2001; 293:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/26\">",
"      Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum 1983; 26:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/27\">",
"      Field M, Williams DG, Charles P, Maini RN. Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens. Ann Rheum Dis 1988; 47:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/28\">",
"      Abuaf N, Johanet C, Chretien P, et al. Detection of autoantibodies to Sm antigen in systemic lupus erythematosus by immunodiffusion, ELISA and immunoblotting: variability of incidence related to assays and ethnic origin of patients. Eur J Clin Invest 1990; 20:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/29\">",
"      McNeilage LJ, Umapathysivam K, Macmillan E, et al. Definition of a discontinuous immunodominant epitope at the NH2 terminus of the La/SS-B ribonucleoprotein autoantigen. J Clin Invest 1992; 89:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/30\">",
"      Scofield RH, Harley JB. Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus. Proc Natl Acad Sci U S A 1991; 88:3343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/31\">",
"      Buyon JP, Ben-Chetrit E, Karp S, et al. Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest 1989; 84:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/32\">",
"      Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/33\">",
"      Jolly M, Smaron M, Olsen Utset T, Ellman M. Are isolated antinucleolar antibodies a marker of scleroderma? J Clin Rheumatol 2003; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/34\">",
"      Bandin O, Courvalin JC, Poupon R, et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/35\">",
"      Sen&eacute;cal JL, Rauch J, Grodzicky T, et al. Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/36\">",
"      Dieud&eacute; M, Sen&eacute;cal JL, Rauch J, et al. Association of autoantibodies to nuclear lamin B1 with thromboprotection in systemic lupus erythematosus: lack of evidence for a direct role of lamin B1 in apoptotic blebs. Arthritis Rheum 2002; 46:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/37\">",
"      Kavanaugh A, Tomar R, Reveille J, et al. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000; 124:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/38\">",
"      Miller MH, Littlejohn GO, Jones BW, Strnad H. Clinical comparison of cultured human epithelial cells and rat liver as substrates for the fluorescent antinuclear antibody test. J Rheumatol 1985; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Rheumatology Position Statement: Methodology of testing for antinuclear antibodies. www.rheumatology.org/practice/clinical/position/ana_position_stmt.pdf (Accessed on September 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/40\">",
"      Reiff A, Haubruck H, Amos MD. Evaluation of a recombinant antigen enzyme-linked immunosorbent assay (ELISA) in the diagnostics of antinuclear antibodies (ANA) in children with rheumatic disorders. Clin Rheumatol 2002; 21:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/41\">",
"      Wallace DJ. New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability? Nat Clin Pract Rheumatol 2006; 2:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/42\">",
"      Moder KG, Wener MH, Weisman MH, et al. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. J Rheumatol 2007; 34:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/43\">",
"      Bonilla E, Francis L, Allam F, et al. Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol 2007; 124:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/44\">",
"      Cook L. New methods for detection of anti-nuclear antibodies. Clin Immunol Immunopathol 1998; 88:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/45\">",
"      Nesher G, Margalit R, Ashkenazi YJ. Anti-nuclear envelope antibodies: Clinical associations. Semin Arthritis Rheum 2001; 30:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/46\">",
"      Earnshaw WC, Migeon BR. Three related centromere proteins are absent from the inactive centromere of a stable isodicentric chromosome. Chromosoma 1985; 92:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28520/abstract/47\">",
"      Davis JM 3rd, Moder KG, Homburger HA, Ytterberg SR. Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies: evidence for autoimmunity including neurologic and connective tissue diseases. Medicine (Baltimore) 2005; 84:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1822 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28520=[""].join("\n");
var outline_f27_54_28520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASES ASSOCIATED WITH A POSITIVE ANA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Systemic autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific organ autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPES OF ANTINUCLEAR ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibodies to double-stranded DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibodies to individual histones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibodies to chromatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibodies to other nuclear proteins and RNA-protein complexes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PERFORMANCE OF THE ANA ASSAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enzyme linked immunosorbent assay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Types and usefulness of staining pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Usefulness of ANA titer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      False positives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      False negatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1822|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/12/42191\" title=\"picture 1\">",
"      LE cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43224\" title=\"picture 2\">",
"      ANA staining patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/31/30205\" title=\"table 1A\">",
"      ANA disease associations I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/7/28797\" title=\"table 1B\">",
"      ANA disease associations II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/28/22988\" title=\"table 2\">",
"      Autoantibodies in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/62/15341\" title=\"table 3\">",
"      Features of drug induced LE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=related_link\">",
"      Miscellaneous antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/61/13265?source=related_link\">",
"      Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=related_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_54_28521="Use of aldosterone antagonists in heart failure";
var content_f27_54_28521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of aldosterone antagonists in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28521/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/54/28521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone antagonist therapy is one component of treatment of patients with systolic heart failure (HF) (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinical trial data has demonstrated that aldosterone antagonist therapy reduces mortality in selected patients with heart failure.",
"   </p>",
"   <p>",
"    The efficacy, risks, and mechanisms of benefit of aldosterone antagonist therapy in systolic HF will be reviewed here. Evaluation and overall management of HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for use of aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) in selected patients with HF comes from randomized trials demonstrating a reduction in mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spironolactone in RALES trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was assessed in the RALES trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This study included 1663 patients with either current New York Heart Association (NYHA) class IV HF or class III HF with a history of class IV HF within the previous six months (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and LVEF &le;35 percent (mean was 25 percent). Previous therapy consisted of an ACE inhibitor and a loop diuretic, with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . The patients were randomly assigned to placebo or a single daily dose of spironolactone (25 to 50 mg daily). Candidates were excluded if they had a serum creatinine concentration &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or a serum potassium concentration &gt;5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    following hemodynamic and electrolyte changes were noted in the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant reductions in systolic and diastolic blood pressure",
"     </li>",
"     <li>",
"      A lower incidence of hypokalemia (0.5 versus 10 percent for placebo)",
"     </li>",
"     <li>",
"      A dose-related increase in the incidence of hyperkalemia (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk of hyperkalemia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After an average follow-up of 24 months, the study was discontinued because of a significant 30 percent reduction in overall mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (35 versus 46 percent for placebo; relative risk 0.70, 95 percent confidence interval [CI] 0.60 to 0.82), due to reductions in death from HF and sudden death, and a 35 percent reduction in hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was evident at three months and persisted for the two-year duration of the study (",
"    <a class=\"graphic graphic_figure graphicRef76232 \" href=\"UTD.htm?31/14/31981\">",
"     figure 1",
"    </a>",
"    ). The improvement in mortality was seen in all patient subsets, including those with an ischemic or nonischemic etiology for HF. The reduction in sudden death may reflect a decrease in the frequency of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocrine side effects characteristic of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (gynecomastia, breast pain, menstrual irregularities, impotence, and decreased libido) were seen in 10 percent compared to 3 percent in the placebo group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Eplerenone in EPHESUS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of selective aldosterone antagonism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    in patients with HF was evaluated in the EPHESUS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/5\">",
"     5",
"    </a>",
"    ]. Study subjects had had a myocardial infarction (MI) 3 to 14 days previously and had an LVEF &le;40 percent (mean 33 percent) with evidence of HF (present in 90 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes mellitus. Candidates were excluded if they had a serum creatinine concentration &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    a serum potassium concentration &gt;5.0",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    or were taking a potassium-sparing diuretic. Eligible patients (n = 6642) were randomly assigned to placebo or eplerenone (25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks, after which the dose of eplerenone was increased to 50",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    16 months, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      had a significantly lower rate of all-cause mortality (14.4 versus 16.7 percent, relative risk (RR) 0.85, 95% CI 0.75 to 0.96), which was entirely due to a reduction in cardiovascular mortality (12.3 versus 14.6 percent). Eplerenone was also associated with significant reductions in sudden cardiac death, which accounted for approximately one-half of the mortality benefit, and hospitalizations for HF. The mortality benefit with eplerenone was significant by 30 days after randomization (3.2 versus 4.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gynecomastia, impotence, or breast pain occurred with equal frequency in both groups (1.0 versus 1.1 percent). The risk of hyperkalemia is described below (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk of hyperkalemia'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the subjects in EPHESUS were also receiving treatment with an ACE inhibitor or angiotensin receptor blocker (87 percent) and a beta blocker (75 percent).",
"   </p>",
"   <p>",
"    It has been estimated that the incremental cost-effectiveness was $10,000 to $22,000 per quality life-year (QALY) gained [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/7\">",
"     7",
"    </a>",
"    ]. This is well below the value of $50,000 to $100,000 per QALY gained that has been considered to be acceptable in the United States and several other countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link&amp;anchor=H10#H10\">",
"     \"A short primer on cost-effectiveness analysis\", section on 'Interpretation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mean LVEF in EPHESUS was 33 percent (compared with 25 percent in RALES), suggesting that patients with less severe HF than seen in the RALES trial might benefit from aldosterone antagonism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the NYHA class of the subjects in EPHESUS was not established, since the patients had had an MI no more than two weeks prior to enrollment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1107515\">",
"    <span class=\"h2\">",
"     Eplerenone in EMPHASIS-HF trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    in selected patients with mildly symptomatic HF was demonstrated in the EMPHASIS-HF trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"     9",
"    </a>",
"    ]. The study enrolled 2737 patients with NYHA class II HF and",
"    <strong>",
"     either",
"    </strong>",
"    an LVEF &le;30 percent",
"    <strong>",
"     or",
"    </strong>",
"    LVEF &gt;30 and &le;35 percent and QRS duration &gt;130 msec. The mean LVEF was 26 percent and only 96 patients were enrolled on the basis of the QRS criterion with LVEF &gt;30 percent. The patients had been hospitalized for a cardiovascular reason (about half had been hospitalized for heart failure) within six months",
"    <strong>",
"     or",
"    </strong>",
"    had a plasma level of B-type natriuretic peptide (BNP) of at least 250",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    or N-terminal pro-BNP of at least 500",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in men and 750",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in women. Study subjects were receiving an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin receptor blocker as well as a beta-blocker (unless contraindicated). Exclusion criteria included serum potassium concentration &gt;5.0",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    an estimated glomerular filtration rate (eGFR) &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , and acute myocardial infarction.",
"   </p>",
"   <p>",
"    The initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    dose of 25 mg per day was increased after four weeks to 50 mg per day (alternatively, the initial dose was 25 mg on alternate day and increasing to 25 mg daily, if the eGFR was 30 to 49",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) provided that the serum potassium level was no more than 5.0 mmol per liter.",
"   </p>",
"   <p>",
"    At 21 months, the study was stopped prematurely, according to prespecified rules, with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      had a significantly lower rate of the primary outcome of death from cardiovascular causes or hospitalization for HF (18.3 versus 25.9 percent in the placebo group, hazard ratio (HR) 0.63; 95% CI 0.54 to 0.74)",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      had a significantly lower mortality rate (12.5 versus 15.5; HR 0.76; 95% CI 0.62 to 0.93) and lower rate of death from cardiovascular causes (HR 0.76; 95% CI 0.61 to 0.94).",
"     </li>",
"     <li>",
"      Hospitalizations for HF and for any cause were also reduced in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of hyperkalemia is described below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Risk of hyperkalemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combination with other HF medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated the efficacy of aldosterone antagonist therapy concurrent with other HF drugs. This was best demonstrated by the EMPHASIS-HF trial in which 94 percent of patients received an ACE inhibitor or ARB and 87 percent received a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In earlier trials, concurrent therapy was less complete. In RALES, 95 percent of patients were treated with an ACE inhibitor, 75 percent with digitalis, but only 11 percent with a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3\">",
"     3",
"    </a>",
"    ]. The benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    was seen in all therapy subgroups. In EPHESUS, 85 percent of patients were treated with an ACE inhibitor or ARB and 75 percent with a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/5\">",
"     5",
"    </a>",
"    ]. The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    was greatest in patients treated with both classes of drugs.",
"   </p>",
"   <p>",
"    Similarly, patients taking an aldosterone antagonist appear to benefit from a beta blocker. This was suggested in a post-hoc analysis from the COPERNICUS trial in which the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    (reduced mortality and HF admissions) were similar in the subsets of patients who were (19 percent) and were not (81 percent) taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the efficacy of an aldosterone antagonist in patients treated with both an ACE inhibitor and an ARB is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/11\">",
"     11",
"    </a>",
"    ]. Given concerns that the concurrent use of these three agents increases the risk of hyperkalemia, the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines with 2009 focused update recommended against such triple therapy (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/12\">",
"     12",
"    </a>",
"    ]. A post-hoc analysis of CHARM-ADDED trial data suggested a possible benefit from adding an ARB to an ACE inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    similar to that in the entire study population without an increase in drug cessation because of hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/13\">",
"     13",
"    </a>",
"    ], but the safety and efficacy of this approach has not been established. In summary, in patients who are appropriate candidates for ACE inhibitor plus aldosterone antagonist therapy, the addition of an ARB is",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link&amp;anchor=H17#H17\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Combination with aldosterone antagonist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK OF HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is an important concern in patients with moderate to severe HF who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RALES trial noted a dose-related increase in the incidence of hyperkalemia (serum potassium &ge;5.5",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      ranging from 5 to 24 percent at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      doses of 12.5 and 75 mg per day, respectively; the incidence of serious hyperkalemia (serum potassium &gt;6",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      was 2 percent overall [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the EPHESUS trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      was associated with a small but significant increase in serious hyperkalemia (serum potassium &ge;6",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      5.5 versus 3.9 percent) and a significantly lower likelihood of developing serious hypokalemia (serum potassium &lt;3.5",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      8.4 versus 13.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the EMPHASIS-HF trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      was associated with a higher rate of serum potassium &gt;5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 11.8 percent versus 7.2 percent in the placebo group, although the rate of a serum potassium &gt;6.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      was similar in the two groups (2.5 and 1.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"       9",
"      </a>",
"      ]. A serum potassium &lt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      was less frequent in the eplerenone group (7.5 versus 11.0 percent in the placebo group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors increase the risk of hyperkalemia among patients treated with aldosterone antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/2,3,5,14-18\">",
"     2,3,5,14-18",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      More severe HF",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Underlying renal dysfunction",
"     </li>",
"     <li>",
"      Volume depletion",
"     </li>",
"     <li>",
"      Higher baseline serum potassium concentration",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      dose &ge;50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Higher ACE inhibitor or angiotensin II receptor blocker dose",
"     </li>",
"     <li>",
"      Combined use of ACE inhibitors and angiotensin II receptor blockers",
"     </li>",
"     <li>",
"      Concomitant beta blocker use",
"     </li>",
"     <li>",
"      Use of potassium supplements or potassium-containing salt substitutes",
"     </li>",
"     <li>",
"      Use of nonsteroidal antiinflammatory drugs",
"     </li>",
"     <li>",
"      Use of certain herbal remedies (",
"      <a class=\"graphic graphic_table graphicRef81242 \" href=\"UTD.htm?11/48/12043\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an analysis of data from EPHESUS, the four independent baseline predictors of hyperkalemia (serum potassium &ge;6.0",
"    <span class=\"nowrap\">",
"     Meq/L)",
"    </span>",
"    were eGFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , history of diabetes mellitus, serum potassium &gt;4.3",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and prior use of antiarrhythmics.",
"   </p>",
"   <p>",
"    Given the frequency of hyperkalemia and the risk factors for its development, careful monitoring is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1100576\">",
"    <span class=\"h2\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal dysfunction is a major risk factor for development of hyperkalemia during aldosterone antagonist therapy. In one report, hyperkalemia (serum potassium &ge;5.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    developed in 15 percent of 551 patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    overall, but in 35 and 63 percent of those with baseline serum creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    and &ge;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the increased risk of hyperkalemia in patients with impaired kidney function, the major randomized trials have excluded patients with evidence of moderate to severe renal dysfunction. The RALES and EPHESUS trials excluded patients with serum creatinine &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the serum creatinine may not accurately reflect glomerular filtration rate. The glomerular filtration rate is better estimated using formulas which take into consideration variables that affect muscle mass and therefore creatinine production including age, race, and gender. The EMPHASIS-HF trial followed this approach in excluding patients with an estimated glomerular filtration rate (eGFR) &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimation of the GFR from either the serum creatinine alone or an estimation equation requires a stable serum creatinine. These parameters cannot be used in patients with a rising or falling serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H1505542#H1505542\">",
"     \"Assessment of kidney function\", section on 'Requirement for stable kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of renal function (even eGFR) are imperfect criteria for identifying patients at risk for developing hyperkalemia during aldosterone antagonist therapy. The risk of development of hyperkalemia is higher in patients with renal dysfunction but some with renal dysfunction will not develop hyperkalemia and might benefit from aldosterone antagonist therapy. However, since clinical trials have excluded patients with serum creatinine &ge;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    or eGFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , the available data are insufficient to determine the benefits and risks of aldosterone antagonist therapy in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aldosterone antagonist usage and hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The publication of the RALES trial led to a marked increase in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . The potential risk of this change in practice was demonstrated by a population-based study from Ontario, Canada in which increased use of spironolactone in HF patients was accompanied by increases in the rates of hospital admissions for hyperkalemia (from 4.0 to 11.0 per 1000) and in-hospital death from hyperkalemia (from 0.7 to 2.0 per 100) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, no increase in hyperkalemia-related hospital admissions was observed despite marked increase in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    use in a population-based study in Tayside, Scotland [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/20\">",
"     20",
"    </a>",
"    ]. This latter study suggests that the risk of hyperkalemia associated with aldosterone antagonist use can be successfully managed by careful monitoring in a clinical setting.",
"   </p>",
"   <p>",
"    Although patients receiving aldosterone antagonist therapy require careful monitoring, this is often not done. In a review of 840 heart failure patients with a new prescription for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , baseline measurements of serum potassium and creatinine were obtained in almost all patients, but one-third had no follow-up measurements within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have suggested that aldosterone antagonist therapy is underutilized among patients with HF who are eligible for such treatment. As an example, among 12,565 patients eligible for aldosterone antagonist therapy at hospitals participating in the Get With the Guidelines-HF (GWTG-HF) registry, only 33 percent received such therapy at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the study population was not strictly limited to patients meeting RALES entry or",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines criteria, so it is not possible to determine whether lack of aldosterone antagonist use was inappropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major, not mutually exclusive mechanisms may contribute to the survival benefit associated with aldosterone antagonism: reduced urinary potassium loss, thereby maintaining a higher serum potassium concentration, and blockade of a deleterious effect of aldosterone on the heart. To the degree that the latter effect is important, a similar benefit would NOT be expected with other potassium-sparing diuretics (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Raising serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone antagonism may preserve serum potassium concentration and thus counter the risk of hypokalemia and associated arrhythmic risk caused by non-potassium sparing diuretics. Support for this mechanism comes from observation of increased arrhythmic mortality in patients with HF treated with non-potassium-sparing diuretics alone in a retrospective analysis of data from the SOLVD trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/22\">",
"     22",
"    </a>",
"    ]. In this study of data from 6797 patients with symptomatic NYHA class II to III HF and an LVEF less than 36 percent, diuretic use, compared to no diuretic use, was associated with a higher incidence of overall mortality, cardiovascular deaths (11.4 versus 4.6 percent per year), and arrhythmic or sudden death. The risk of arrhythmic death associated with the use of non-potassium-sparing diuretics was significantly elevated (relative risk 1.33) after controlling for disease severity, comorbid illnesses, and concomitant medications including ACE inhibitors. In comparison, there was no association between arrhythmic death and use of a potassium-sparing diuretic, either alone or in combination with a non-potassium-sparing agent.",
"   </p>",
"   <p>",
"    However, it seems unlikely that maintenance of serum potassium concentration is the main mechanism for aldosterone antagonist benefit in HF. In the RALES trial, a similar significant mortality benefits were seen in patients with median potassium levels &ge;4.2 and &lt;4.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blocking aldosterone effect on the heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the importance of blocking the effects of aldosterone on the heart comes in part from two observations: the heart contains mineralocorticoid receptors and aldosterone is produced locally in the diseased heart in proportion to the severity of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/23\">",
"     23",
"    </a>",
"    ]. The latter effect is mediated by the induction of aldosterone synthase (CYP11B2) by angiotensin II in the failing ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activatable mineralocorticoid receptors are also present in coronary artery and aortic vascular smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/25\">",
"     25",
"    </a>",
"    ]. These receptors can be activated by aldosterone as well as by angiotensin II, thus inhibition of this system may contribute to the beneficial effects of angiotensin inhibition in patients with HF. Activation of these receptors may also contribute to the increased incidence of stroke and coronary events in patients with primary aldosteronism compared to matched patients with essential hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Locally produced aldosterone may create a vicious cycle by stimulating angiotensin converting enzymes in the local renin-angiotensin system, an effect blocked by aldosterone antagonism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct effects of aldosterone on the heart may include promoting the development of cardiac hypertrophy and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/30\">",
"     30",
"    </a>",
"    ], and, with chronic pressure overload, the transition from hypertrophy to heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for a pathogenetic role for aldosterone in humans with HF comes from the following observations in RALES [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with higher serum concentrations of markers of collagen synthesis (procollagen type I carboxy-terminal peptide, procollagen type I amino-terminal peptide, and procollagen type III amino-terminal peptide) had higher rates of death and hospitalization.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    but not placebo reduced the serum concentrations of these markers, and the survival benefit of spironolactone was primarily seen in patients with higher procollagen concentrations. The reduction in procollagen type III amino-terminal peptide also correlated with an improvement in left ventricular remodeling and a reduction in the serum concentrations of atrial and brain natriuretic peptide, which are markers of myocardial remodeling, disease severity, and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pilot trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    in patients with idiopathic dilated cardiomyopathy and mild symptoms (NYHA class I or II) also provided support for a pathogenetic role of aldosterone on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/34\">",
"     34",
"    </a>",
"    ]. Benefit from spironolactone (improved left ventricular diastolic function and regression of myocardial fibrosis) was only seen in patients with increased myocardial collagen accumulation at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect of ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It might be thought that aldosterone antagonism would be less likely to be of benefit in patients treated with ACE inhibitors. Angiotensin II is the major physiologic stimulus to aldosterone secretion; as a result, reducing angiotensin II production with an ACE inhibitor should lower plasma aldosterone levels. However, the benefits in RALES and EPHESUS occurred in patients treated with ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation is that many patients with HF treated with an ACE inhibitor have plasma aldosterone concentrations above the upper limit of normal (11 of 34 in one report), often with virtually complete inhibition of vascular angiotensin converting enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/35\">",
"     35",
"    </a>",
"    ]. The stimulus to aldosterone secretion in such patients could be mediated by tissue renin-angiotensin systems not inhibited by the ACE inhibitor, angiotensin II generation via pathways not requiring angiotensin converting enzyme, or other stimuli such as a high serum potassium concentration, which is not uncommon in patients with advanced HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2683340\">",
"    <span class=\"h2\">",
"     Other endocrine effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    compete for the mineralocorticoid receptor with aldosterone. The endocrine side effects of spironolactone (gynecomastia, breast pain, menstrual irregularities, impotence, and decreased libido) result from nonselective binding to androgen and progesterone receptors (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes and evaluation of gynecomastia\", section on 'Drugs'",
"    </a>",
"    ). Eplerenone has greater specificity than spironolactone for the mineralocorticoid receptor resulting in a lower incidence of endocrine side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    heart failure guidelines with 2009 update recommended addition of an aldosterone antagonist in selected patients with moderately severe to severe symptoms of HF and a reduced LVEF who can be carefully monitored for preserved renal function and a normal serum potassium concentration (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The baseline serum creatinine concentration should be &le;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in men and &le;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in women and the serum potassium concentration should be &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    An aldosterone antagonist was",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients treated with both an ACE inhibitor and an ARB.",
"   </p>",
"   <p>",
"    The 2008 European Society of Cardiology HF guidelines and the 2010 Heart Failure Society of America guidelines include similar recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EMPHASIS-HF trial, which provided evidence for the efficacy of aldosterone antagonist in selected patients with mild heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"     9",
"    </a>",
"    ], was published after the above guidelines.",
"   </p>",
"   <p>",
"    Among patients who have had a recent myocardial infarction, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on ST elevation myocardial infarction recommended long-term aldosterone blockade in patients who are already receiving therapeutic doses of an ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic HF or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/38\">",
"     38",
"    </a>",
"    ]. The same restrictions as in the heart failure guidelines were noted for renal function and serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1100623\">",
"    <span class=\"h2\">",
"     Selection of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general agreement with the above major society guidelines, we recommend administration of an aldosterone antagonist to patients who satisfy requirements for renal function and serum potassium and fulfill the criteria of RALES (current or recent NYHA class IV HF and LVEF &le;35 percent) or the entry criteria in EPHESUS (recent myocardial infarction and LVEF &le;40 percent plus symptomatic HF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In addition, the EMPHASIS-HF trial supports treatment of selected patients with NYHA class II HF and LVEF &le;30 percent and recent hospitalization for a cardiovascular reason or elevated plasma BNP or N-terminal pro-BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We recommend aldosterone antagonist therapy to treat HF in patients who meet one or more of the following criteria if they can be carefully monitored for changes in serum potassium and renal function. The serum potassium should be &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and eGFR should be &ge;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with NYHA functional class II HF and LVEF &le;30 percent.",
"     </li>",
"     <li>",
"      Patients with NYHA functional class III to IV HF and LVEF &lt;35 percent.",
"     </li>",
"     <li>",
"      Patients post-ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link&amp;anchor=H30#H30\">",
"       \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Aldosterone antagonists'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, the RALES and EPHESUS trials excluded patients with serum creatinine &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    We favor the approach taken in the EMPHASIS-HF study which excluded patients with eGFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , since eGFR is a more accurate estimate of renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2683273\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    is associated with fewer endocrine side effects (gynecomastia) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (1 versus 10 percent in the respective trials), this advantage must be weighed against the marked difference in cost between the two drugs. It may be reasonable to begin with spironolactone (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and switch to eplerenone (25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and after four weeks 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    if endocrine side effects occur.",
"   </p>",
"   <p>",
"    Other potassium-sparing diuretics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used concurrently with or in place of aldosterone antagonists. To the degree that blockade of a deleterious effect of aldosterone on the heart is important, a similar benefit would",
"    <strong>",
"     not",
"    </strong>",
"    be expected with other potassium-sparing diuretics (such as amiloride).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1101284\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the eGFR is &ge;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , we suggest starting with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and after four weeks increasing to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if serum potassium is &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    A switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and after four weeks increasing to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if serum potassium is &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    is recommended if endocrine side effects occur.",
"   </p>",
"   <p>",
"    If the eGFR is 30 to 49",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    should be 25 mg on alternate days (or 12.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and after four weeks increasing to 25 mg daily if the serum potassium is &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    A switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    (25 mg on alternate days and after four weeks 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if serum potassium is &lt;5.0",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    is recommended if endocrine side effects occur.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    should be reduced if serum potassium levels rise. As in the EPHESUS and EMPHASIS-HF trials, if the serum potassium level is 5.5 to 5.9",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the dose should be decreased (eg, from 50 to 25",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    from 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 25 mg every other day, or from 25 mg every other day to stop) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. If the serum potassium level is &ge;6.0",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    the drug should be discontinued until serum potassium is &lt;5.5",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1101253\">",
"    <span class=\"h2\">",
"     Timing of initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data suggest that inclusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    therapy at discharge from hospitalization for HF exacerbation may reduce mortality. In a study of 946 patients hospitalized with systolic HF, discharge use of spironolactone was associated with reduced all-cause death at 2.2 years (adjusted hazard ratio 0.62; 95% CI 0.41-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/39\">",
"     39",
"    </a>",
"    ]. However, this study did not compare initiation by discharge with later initiation.",
"   </p>",
"   <p>",
"    The mortality benefit in the EPHESUS trial was significant by 30 days (3.2 versus 4.6 percent), suggesting that an aldosterone antagonist should be started before discharge in patients who fulfill the EPHESUS criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2683266\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    should undergo serial monitoring of the serum potassium concentration because of the potential for severe hyperkalemia, particularly with worsening HF and concomitant ACE inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. A specific approach to minimizing the risk of hyperkalemia has been proposed (",
"    <a class=\"graphic graphic_table graphicRef67783 \" href=\"UTD.htm?31/16/32011\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28521/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Risk of hyperkalemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Serum potassium concentration should be measured periodically (eg, within one week of starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    and at four weeks, as well as every few months) as well as after dosage increases, changes in concomitant diuretic dose, and when change in renal function or electrolyte status is suspected (eg, vomiting or diarrhea).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1107627\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Support for use of an aldosterone antagonist in selected patients with systolic HF comes from randomized trials in which treatment with these agents reduced mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two major mechanisms may contribute to the survival benefit associated with aldosterone antagonism: reduced urinary potassium loss, thereby maintaining a higher serum potassium concentration, and blockade of a deleterious effect of aldosterone on the heart. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend aldosterone antagonist therapy to treat HF in patients who have NYHA functional class II HF and an LVEF &le;30 percent, or NYHA functional class III to IV HF and an LVEF &lt;35 percent, who can be carefully monitored for serum potassium and renal function (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also recommend aldosterone antagonist therapy for patients post ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus, who can be carefully monitored for serum potassium and renal function (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The serum potassium should be &lt;5.0",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and eGFR should be &ge;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      therapy should undergo serial monitoring of serum potassium and renal function. A specific approach to minimizing hyperkalemia has been proposed (",
"      <a class=\"graphic graphic_table graphicRef67783 \" href=\"UTD.htm?31/16/32011\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2683266\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk of hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aldosterone antagonist therapy is effective in combination with beta blocker therapy and ACE inhibitor or ARB therapy. However, the combination of aldosterone antagonist therapy and ACE inhibitor plus ARB therapy is",
"      <strong>",
"       not",
"      </strong>",
"      generally recommended. In patients who are appropriate candidates for ACE inhibitor plus aldosterone antagonist therapy, the addition of an ARB is",
"      <strong>",
"       not",
"      </strong>",
"      generally recommended. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Combination with other HF medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/1\">",
"      de Gasparo M, Joss U, Ramjou&eacute; HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/2\">",
"      Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/3\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/4\">",
"      Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/5\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/6\">",
"      Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/7\">",
"      Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005; 111:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/8\">",
"      Jessup M. Aldosterone blockade and heart failure. N Engl J Med 2003; 348:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/9\">",
"      Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/10\">",
"      Krum H, Mohacsi P, Katus HA, et al. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J 2006; 151:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/11\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/12\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/13\">",
"      Weir RA, McMurray JJ, Puu M, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/14\">",
"      Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/15\">",
"      Wrenger E, M&uuml;ller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/16\">",
"      Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/17\">",
"      Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005; 46:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/18\">",
"      Pitt B, Bakris G, Ruilope LM, et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/19\">",
"      Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/20\">",
"      Wei L, Struthers AD, Fahey T, et al. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340:c1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/21\">",
"      Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009; 302:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/22\">",
"      Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/23\">",
"      Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/24\">",
"      Silvestre JS, Heymes C, Oub&eacute;na&iuml;ssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/25\">",
"      Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/26\">",
"      Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/27\">",
"      Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/28\">",
"      Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/29\">",
"      Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/30\">",
"      Ouvrard-Pascaud A, Sainte-Marie Y, B&eacute;nitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/31\">",
"      Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/32\">",
"      Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/33\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/34\">",
"      Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005; 112:2940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/35\">",
"      Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002; 106:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/36\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/37\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/38\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28521/abstract/39\">",
"      Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 2010; 160:1156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3464 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28521=[""].join("\n");
var outline_f27_54_28521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1107627\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spironolactone in RALES trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Eplerenone in EPHESUS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1107515\">",
"      Eplerenone in EMPHASIS-HF trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combination with other HF medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK OF HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1100576\">",
"      Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aldosterone antagonist usage and hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Raising serum potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blocking aldosterone effect on the heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect of ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2683340\">",
"      Other endocrine effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1100623\">",
"      Selection of patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2683273\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1101284\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1101253\">",
"      Timing of initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2683266\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1107627\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3464|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/14/31981\" title=\"figure 1\">",
"      Spironolactone in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12043\" title=\"table 3\">",
"      Herbal causes hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/16/32011\" title=\"table 4\">",
"      Approach high K RAAS blockers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=related_link\">",
"      Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_54_28522="Epidemiology of and risk factors for atrial fibrillation";
var content_f27_54_28522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of and risk factors for atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/54/28522/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/54/28522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is a relatively common arrhythmia that may cause significant symptoms and impair both functional status and the quality of life. Affected patients may be at increased risk for mortality (1.5- to 1.9-fold in the Framingham study), for deterioration in hemodynamics due to increased heart rate, loss of atrioventricular (AV) synchrony, and progressive dysfunction of the left atrium and left ventricle, and for stroke and other embolic events from atrial thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of and disease associations with AF will be reviewed here. An overview of the presentation and management of patients with AF is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of AF depends upon the population studied; the risk increases with age and with underlying heart disease (",
"    <a class=\"graphic graphic_figure graphicRef82929 \" href=\"UTD.htm?33/19/34098\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The following data are primarily derived from studies in which an ECG was obtained during an office visit rather than ambulatory monitoring. The prevalence of paroxysmal AF, which is more likely to be detected with ambulatory monitoring, is much higher.",
"   </p>",
"   <p>",
"    AF is uncommon in infants and children and when present, almost always occurs in association with structural heart disease. Healthy young adults are also at low risk; in one report, for example, only five of over 122,000 routinely evaluated, healthy Air Force personnel had AF on a screening ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of AF is greater in older subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/2-5,7\">",
"     2-5,7",
"    </a>",
"    ]. This relationship to age was demonstrated in the ATRIA study, a cross-sectional study of almost 1.9 million subjects in a health maintenance organization in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/7\">",
"     7",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of AF was 1 percent; 70 percent were at least 65 years old and 45 percent were &ge;75 years old.",
"     </li>",
"     <li>",
"      The prevalence of AF ranged from 0.1 percent among adults less than 55 years of age to 9 percent in those &ge;80 years of age (",
"      <a class=\"graphic graphic_figure graphicRef77268 \" href=\"UTD.htm?2/14/2286\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The prevalence was higher in men than women (1.1 versus 0.8 percent), a difference seen in every age group (",
"      <a class=\"graphic graphic_figure graphicRef77268 \" href=\"UTD.htm?2/14/2286\">",
"       figure 2",
"      </a>",
"      ). Among subjects over 50, AF was more frequent in whites than blacks (2.2 versus 1.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar patterns were reported in a European population-based prospective cohort study of 6808 subjects &ge;55 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of AF was 5.5 percent, ranging from 0.7 percent in those aged 55 to 59 years and 17.8 percent for those &ge; 85 years of age. The prevalence was higher in men than women (6.0 versus 5.1 percent).",
"   </p>",
"   <p>",
"    The prevalence of AF in the population is increasing. In a community-based study of 1.4 million patients in England and Wales, the age-standardized prevalence of AF between 1994 and 1998 increased by 22 and 14 percent in men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ATRIA study, it was estimated that 2.3 million adults in the United States had AF in",
"    <span class=\"nowrap\">",
"     1996/1997,",
"    </span>",
"    and that this will increase to 5.6 million by the year 2050, with more than 50 percent being more than 80 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/7\">",
"     7",
"    </a>",
"    ]. In a more recent report from the United States, the prevalence of AF in 2005 was 3.03 million, and the projected prevalence for 2050 was 7.56 million [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102126448\">",
"    <span class=\"h3\">",
"     Subclinical AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical AF refers to asymptomatic episodes in a patient without a prior history of AF, which are detected only by monitoring techniques. As mentioned above, the prevalence of AF depends on the population studied. Prevalence is also influenced by the duration, sensitivity, and specificity of screening techniques. Several studies have investigated the prevalence of subclinical AF. The following studies are examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ASSERT study monitored (using a dual chamber pacemaker or implantable cardioverter defibrillator) 2580 patients, 65 years or older, with hypertension and no history of AF for the development of AF (defined as episodes of atrial rate &gt;190 beats per minute for more than six minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/9\">",
"       9",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At three months, about 10 percent of patients developed AF. The median number of episodes was two and the median time to detection of the first episode was 36 days.",
"     </li>",
"     <li>",
"      At 2.5 years, about 35 percent of individuals developed subclinical AF. Clinical AF developed in about 16 percent of patients with subclinical AF.",
"     </li>",
"     <li>",
"      This study also evaluated the relationship between the presence of subclinical AF and stroke. This issue is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H19246582#H19246582\">",
"       \"Cryptogenic stroke\", section on 'Subclinical atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 56 patients with cryptogenic transient ischemic attack TIA or stroke who were evaluated with an outpatient mobile cardiac monitor for a mean of 21 days, AF was detected in 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 149 patients with cryptogenic TIA or stroke who were evaluated with either a 24 hour Holter monitor or, if that study was normal, an event-loop recording device for seven days, AF was detect in 11 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of AF, like the prevalence, increases with advancing age and with the presence of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/5,12-14\">",
"     5,12-14",
"    </a>",
"    ]. In a longitudinal study in which 3983 male Air Force recruits were followed for 44 years, 7.5 percent developed AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk increased with advancing age (from 0.5 per 1000 person-years before age 50 to 9.7 per 1000 person years after age 70) (",
"    <a class=\"graphic graphic_figure graphicRef67898 \" href=\"UTD.htm?21/61/22493\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lifetime risk for the development of AF was analyzed in a report from the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/15\">",
"     15",
"    </a>",
"    ]. A total of 8725 patients were followed from 1968 to 1999 (176,166 person-years of follow-up); 936 developed AF. The risk of developing AF from age 40 to age 95 was 26 percent for men and 23 percent for women. Lifetime risk did not change substantially with increasing index age because AF incidence rose with age; the risk of developing AF from age 80 to age 95 was 23 percent for men and 22 percent for women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK PREDICTION MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Models that attempt to predict the risk of development of atrial fibrillation have been developed. Using the Framingham Heart Study population, age, sex, systolic blood pressure, treatment for hypertension, PR interval, clinically significant cardiac murmur, body mass index, and heart failure, were incorporated into a risk prediction model that predicts an individual's absolute risk over 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/16\">",
"     16",
"    </a>",
"    ]. This model has been validated in two geographically and racially diverse cohorts in the age range of 45 to 95 years and predicted the five-year incidence of AF with moderate accuracy (C statistic 0.66 to 0.68) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the benefit of using risk prediction models in this setting has not been established. There are no studies linking this with improved outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF has been classified as paroxysmal, persistent, permanent, or \"lone\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/18\">",
"     18",
"    </a>",
"    ]. This classification system is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H439358969#H439358969\">",
"     \"Overview of atrial fibrillation\", section on 'Lone AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrespective of the underlying risk factor(s), changes in the electrophysiology of the atrial myocardium are likely important. Sustained AF seems to require the development of multiple wavelets, rather than the single wavefront as seen in atrial flutter. As AF becomes established, the refractory period of the atrial muscle shortens. This electrophysiologic change predisposes to further AF (ie, AF begets AF). Conversely, when sinus rhythm is sustained, these electrophysiologic changes reverse (sinus rhythm begets sinus rhythm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AF is usually associated with some underlying heart disease. Atrial enlargement, an elevation in atrial pressure, or infiltration or inflammation of the atria are often seen. The Framingham Heart Study performed a prospective evaluation of the echocardiographic predictors of AF in individuals without rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/19\">",
"     19",
"    </a>",
"    ]. Left atrial enlargement was shown to precede and predispose to AF. Other echocardiographic risk factors for AF were increased left ventricular wall thickness and reduced left ventricular fractional shortening.",
"   </p>",
"   <p>",
"    Several series in which Holter monitoring was performed have shown that the majority of episodes of paroxysmal AF (PAF) are triggered by atrial premature beats [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], while a small number of PAF episodes are preceded by typical atrial flutter or atrial tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/22\">",
"     22",
"    </a>",
"    ]. Ectopic foci are most often located near the pulmonary veins, occurring in 89 and 94 percent of cases in two series comprised predominantly of patients with minimal or no structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Other foci are located in the right and left atria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/21\">",
"     21",
"    </a>",
"    ]. The importance of the pulmonary veins in the genesis of PAF is further illustrated by the beneficial effect of pulmonary vein isolation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial premature beats appear to be most important as a trigger in patients with PAF who have normal or near-normal hearts. The relative importance of atrial premature beats or other triggers versus an abnormal substrate is much less clear in patients with significant structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that may contribute to AF in these patients include increased vagal tone and possible subclinical myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LONE AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with paroxysmal or persistent AF have no underlying structural heart disease; such patients are considered to have lone AF. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H439358969#H439358969\">",
"     \"Overview of atrial fibrillation\", section on 'Lone AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive heart disease and coronary heart disease (CHD) are the most common underlying disorders in patients with AF in developed countries. Rheumatic heart disease, although now uncommon in developed countries, is associated with a much higher incidence of AF. Paroxysmal AF is associated with the same disorders as chronic (permanent) AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypertensive heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between hypertension and AF was illustrated in the longitudinal study of male air crew recruits noted above: a history of hypertension increased the risk of developing AF 1.42-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/14\">",
"     14",
"    </a>",
"    ]. Although this is a relatively small increase in risk, the high frequency of hypertension in the general population results in hypertensive heart disease being the most common underlying disorder in patients with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is not commonly associated with CHD unless it is complicated by acute myocardial infarction (MI) or heart failure. AF occurs transiently in 6 to 10 percent of patients with an acute myocardial infarction (MI), presumably due to atrial ischemia or atrial stretching secondary to heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. These patients have a worse prognosis that is mostly due to comorbidities such as older age and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=see_link&amp;anchor=H5#H5\">",
"     \"Supraventricular arrhythmias after myocardial infarction\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of AF is much lower in patients with chronic stable CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In the Coronary Artery Surgical Study (CASS), which included over 18,000 patients with angiographically documented coronary artery disease, AF was present in only 0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/27\">",
"     27",
"    </a>",
"    ]. These patients probably had chronic AF; the prevalence of paroxysmal AF may be higher. AF was associated with age greater than 60, male sex, mitral regurgitation, and heart failure; there was no association between AF and the number of coronary arteries involved.",
"   </p>",
"   <p>",
"    CASS and other studies found that AF was an independent predictor of increased mortality in patients with stable CHD. In CASS, the relative risk was 1.98 at seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     AF as a presentation of ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF is an infrequent manifestation of an acute MI or coronary ischemia in the absence of other signs or symptoms of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost any valvular lesion that leads to significant stenosis or regurgitation is associated with the development of AF. The following are representative frequencies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 89 patients with mitral valve prolapse (and grade 3 or 4 MR) and 360 with flail leaflets, the rate of development of AF was about 5 percent per year with both types of lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/31\">",
"       31",
"      </a>",
"      ]. The major independent risk factors were age &ge;65 years and baseline left atrial dimension &ge;50 mm.",
"     </li>",
"     <li>",
"      Rheumatic heart disease is now uncommon in developed countries. It is, however, associated with a high prevalence of AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In a study of approximately 1100 patients with rheumatic heart disease, the prevalence varied with the type of valve disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/33\">",
"       33",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mitral stenosis (MS), mitral regurgitation (MR), and tricuspid regurgitation &mdash; 70 percent",
"     </li>",
"     <li>",
"      MS and MR &mdash; 52 percent",
"     </li>",
"     <li>",
"      Isolated MS &mdash; 29 percent",
"     </li>",
"     <li>",
"      Isolated MR &mdash; 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation and heart failure (HF) often occur together, and each may predispose to the other. Among patients with HF, the prevalence of AF is variable, depending in part upon the severity of HF. Issues related to AF in patients with HF and cardiomyopathy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF has been reported in 10 to 28 percent of patients with hypertrophic cardiomyopathy (HCM) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The prognostic importance of AF in these patients is unclear, with some reports showing a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/36\">",
"     36",
"    </a>",
"    ] and others no increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link\">",
"     \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF has been reported in approximately 20 percent of adults with an atrial septal defect [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the incidence of AF is related to age, ranging in one series from 15 percent for those aged 40 to 60, to 61 percent for those over the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flutter also occurs in other forms of congenital heart disease that affect the atria, including Ebstein's anomaly and patent ductus arteriosus, and after surgical correction of some other abnormalities, including ventricular septal defect, tetralogy of Fallot, pulmonic stenosis, and transposition of the great vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other types of cardiopulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF is associated with a variety of other types of cardiopulmonary disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AF is seen in 10 to 14 percent of patients with documented pulmonary embolism (PE) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. It is rarely the only sign or symptom of acute PE.",
"     </li>",
"     <li>",
"      AF also occurs in chronic obstructive pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/41,42\">",
"       41,42",
"      </a>",
"      ], peripartum cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/43\">",
"       43",
"      </a>",
"      ], lupus myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/44\">",
"       44",
"      </a>",
"      ], and both idiopathic and uremic pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a possible causal relationship between obstructive sleep apnea (OSA) and AF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/47-50\">",
"       47-50",
"      </a>",
"      ]. In a series of 39 patients diagnosed with both PAF and OSA, patients receiving treatment with continuous positive pressure ventilation had a lower incidence of AF recurrence at 12 months (42 percent, versus 82 percent for patients who were not treated) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/47\">",
"       47",
"      </a>",
"      ]. In another observational study, the incidence of OSA was compared between 151 patients referred for cardioversion for AF and 312 controls without AF referred for general cardiology evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/48\">",
"       48",
"      </a>",
"      ]. OSA was significantly more common in the patients with AF than in the control group (49 versus 32 percent). Finally, preoperative sleep studies were performed in a series of 121 patients referred for coronary artery bypass surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/49\">",
"       49",
"      </a>",
"      ]. Post operative AF was significantly more common among the 49 patients with an abnormal sleep study (39 versus 18 percent in patients with normal sleep studies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H11#H11\">",
"       \"Cardiovascular effects of obstructive sleep apnea\", section on 'Cardiac arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese individuals (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    are significantly more likely to develop atrial fibrillation than those with a normal BMI (&lt;25",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased left atrial pressure and volume as well as a shortened effective refractory period in the left atrium and in the proximal and distal pulmonary veins have been identified as potential factors facilitating and perpetuating AF in obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link\">",
"     \"Mechanisms of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177150160\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of over 4700 individuals without valvular heart disease in the Framingham Heart Study, the presence of diabetes was associated with a significantly increased risk for the development of AF in multivariate analysis (OR, 1.1 for men and 1.5 for women) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/52\">",
"     52",
"    </a>",
"    ]. Increased left ventricular mass and increased arterial stiffness have been put forth as possible mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the presence of hypertension, diabetes, or obesity is associated with an increased likelihood of the development of AF. The metabolic syndrome includes these three, as well as dyslipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H2#H2\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential relationship between the metabolic syndrome and the development of AF was evaluated in a prospective, observational cohort study of 28,449 Japanese citizens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/54\">",
"     54",
"    </a>",
"    ]. Using the 2005 criteria for the metabolic syndrome approved by the American Heart Association and the National Heart, Lung, and Blood Institute, 4544 individuals met criteria for the metabolic syndrome at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/55\">",
"     55",
"    </a>",
"    ]. During a mean follow-up for 4.5 years, AF developed in 265 patients. The risk of developing AF was significantly greater in those individuals with the metabolic syndrome (hazard ratio 1.61, 95% CI 1.21-2.15), as well as in those with individual components of hypertension, obesity, low HDL cholesterol and impaired glucose tolerance, but not elevated triglycerides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism have an increased risk of developing AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/56\">",
"     56",
"    </a>",
"    ]. In one population-based study of 40,628 patients with clinical hyperthyroidism, 8.3 percent had atrial fibrillation or flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/57\">",
"     57",
"    </a>",
"    ]. Atrial fibrillation occurred in 10 to 20 percent of patients over age 60 but in less than 1 percent of patients under age 40. Men were more likely to have AF than women (12.1 versus 7.6 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link&amp;anchor=H6#H6\">",
"     \"Cardiovascular effects of hyperthyroidism\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased beta adrenergic tone may be in part responsible for the development of AF in hyperthyroidism and may also contribute to the rapid ventricular response in this setting. In addition, excess thyroid hormone increases the likelihood of AF in experimental animals, even in the presence of beta receptor and vagal blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/58\">",
"     58",
"    </a>",
"    ]; it is likely that this observation applies to humans. The mechanism is unknown, but may be related to an increased automaticity and enhanced triggered activity of pulmonary vein cardiomyocytes, which can be a source of ectopic beats that initiate AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of AF is also increased in patients with",
"    <strong>",
"     subclinical hyperthyroidism",
"    </strong>",
"    (defined as a low serum thyroid stimulating hormone [TSH] concentration and normal serum thyroid hormone concentrations) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The increase in risk is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 2007 subjects &ge;60 years of age who did not have AF were followed for 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/60\">",
"       60",
"      </a>",
"      ]. The subsequent age-adjusted incidence of AF was significantly higher among those with a low serum TSH concentration compared to those with a normal value (28 versus 10 per 1000 person-years).",
"     </li>",
"     <li>",
"      In a review of 23,638 subjects, the prevalence of AF in those with clinical and subclinical hyperthyroidism was similar (14 and 13 percent, respectively) and higher than that in euthyroid subjects (2.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these observations, serum TSH should be measured as part of the initial evaluation in all patients with AF in whom a cause is not present, even if there are no symptoms suggestive of thyrotoxicosis. Those with low values (&lt;0.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    with the newer sensitive assays) and normal serum T4 probably have subclinical hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible relationship between AF and hypothyroidism has been suggested but not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Since hypothyroidism is present in 5 to 10 percent of the general population, it is not surprising that some patients with AF have hypothyroidism (7.7 percent with subclinical disease in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/62\">",
"     62",
"    </a>",
"    ]) that may not be causally related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118325398\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;CKD increases the risk of the development of AF. The following two prospective, cohort studies are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 235, 818 individuals, the hazard ratio for the development of AF was 1.32 for patients with eGFRs of 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min/1.73m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      compared to those with normal renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relationship between CKD and AF was evaluated in a report of 10, 328 individuals free of AF participating in the Atherosclerosis Risk in Communities (ARIC) study who had a baseline cystatin C-based estimated glomerular filtration rate (eGFR",
"      <sub>",
"       cys",
"      </sub>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/66\">",
"       66",
"      </a>",
"      ]. Compared to individuals with eGFR",
"      <sub>",
"       cys",
"      </sub>",
"      &ge;90",
"      <span class=\"nowrap\">",
"       mL/min/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      the multivariable hazard ratios for the development of AF were significantly increased at 1.3, 1.6, and 3.2 in those with eGFR",
"      <sub>",
"       cys",
"      </sub>",
"      of 60-89, 30-59, and 15-29",
"      <span class=\"nowrap\">",
"       mL/min/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      respectively during a median follow-up of 10.1 years. In addition macroalbuminuria and microalbuminuria were significantly associated with higher AF risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence and prevalence of AF in patients with CKD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39721?source=see_link&amp;anchor=H344021238#H344021238\">",
"     \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\", section on 'Prevalence and incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation occurs in relation to a variety of different types of surgery, with the incidence is greatest in patients undergoing coronary artery bypass graft (CABG) or cardiac valve surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF has been reported in up to 30 to 40 percent of patients in the early postoperative period following CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/67-70\">",
"     67-70",
"    </a>",
"    ], in 37 to 50 percent after valve surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/67,70,71\">",
"     67,70,71",
"    </a>",
"    ], and in as many as 60 percent undergoing valve replacement plus CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF has been described in 10 to 24 percent of patients with a denervated transplanted heart, often in the absence of significant rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. Most episodes occur within the first two weeks, while AF developing after two weeks may be associated with an increased risk of subsequent death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link&amp;anchor=H5#H5\">",
"     \"Arrhythmias following cardiac transplantation\", section on 'Supraventricular arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Noncardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF is less common after noncardiac compared to cardiac surgery. The largest experience comes from a review of 4181 patients over the age of 50 who were in sinus rhythm prior to major noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/74\">",
"     74",
"    </a>",
"    ]. The incidence of perioperative AF was 4.1 percent; most episodes occurred within the first three days after surgery. The risk was greatest with intrathoracic surgery (odds ratio 9.2).",
"   </p>",
"   <p>",
"    In another series of 2588 undergoing noncardiac thoracic surgery, the incidence of AF was 12.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to structural heart disease, a number of other factors are associated with an increased risk for the development of AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262710213\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of AF in a first-degree relative, particularly a parent, has long been associated with an increase in risk, independent of standard risk factors such as age, sex, hypertension, diabetes, or clinically overt heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Disease associations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In an analysis of over 4400 individuals in the Framingham Heart Study, the occurrence of AF in a first degree relative was associated with a significantly increased risk of incident AF (multivariable-adjusted hazard ratio 1.40, 95% CI 1.13-1.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/77\">",
"     77",
"    </a>",
"    ]. The strength of this relationship was greater when only first-degree relatives with premature onset (age &le;65 years) were considered.",
"   </p>",
"   <p>",
"    Adjustment for four single-nucleotide polymorphisms (SNPs), tagging validated genome-wide significant AF susceptibility signals, did not significantly alter the association. However, as this study did not take into account all known relevant SNPs, and as others are likely to be identified, it is possible that much of the increased risk associated with family history is attributable to genetic variants. (See",
"    <a class=\"local\" href=\"#H262710391\">",
"     'Genetic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262710391\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with AF, one or more of the disease associations discussed above are present. In patients with lone AF, the cause(s) is unclear. In these patients, and perhaps in many of those with disease associations, a genetic basis may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H439358969#H439358969\">",
"     \"Overview of atrial fibrillation\", section on 'Lone AF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The heritability of AF is complex. For the majority of patients, genetic susceptibility, if present, is probably a polygenic phenomenon, meaning that it is due to the combined effects of a number of genes. Polygenic inheritance can explain why some diseases cluster in families, but do not demonstrate the classic Mendelian inheritance patterns of monogenic disorders. However, a small number of families demonstrate monogenic inheritance characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262710418\">",
"    <span class=\"h3\">",
"     Polygenic inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polygenic inheritance appears to be more common and could explain the modest elevation in the relative risk of AF in first- and second-degree relatives of affected individuals. Evidence supporting a heritable component to AF susceptibility includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 914 patients with AF, 50 (5 percent) had a family history of AF (one to nine additional relatives affected) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 2243 offspring in the Framingham Heart Study, those with parental AF had a significantly higher incidence of developing AF than those without parental AF (4.1 versus 2.7 percent, adjusted odds ratio 1.85) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/76\">",
"       76",
"      </a>",
"      ]. This effect was more pronounced when the analysis was limited to patients with age of AF onset less than 75 years and to those without prior MI, heart failure, or valve disease (odds ratio 3.17).",
"     </li>",
"     <li>",
"      A population study in Iceland evaluated the heritability of AF in a cohort of 5269 patients diagnosed over a 16 year period [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/79\">",
"       79",
"      </a>",
"      ]. Among patients with AF, the degree of relatedness was significantly greater than among matched controls. In addition, the relative risk of developing AF was higher in the relatives of patients than those of controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262710425\">",
"    <span class=\"h3\">",
"     Monogenic inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some families have been identified in which AF inheritance follows more typical Mendelian patterns, consistent with a single disease-causing gene. Both autosomal dominant and autosomal recessive forms have been identified. Genetic linkage analysis has identified loci at 10q22-q24, 11p15.5, 6q14-16, 3p22-p25, and 4q25 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. At the 4q25 locus, several single-nucleotide polymorphisms have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/85\">",
"     85",
"    </a>",
"    ]. In these individuals, penetrance is variable and the polymorphisms can affect the clinical expression of familial AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An autosomal recessive pattern of AF inheritance was reported in a large family from Uruguay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/87\">",
"     87",
"    </a>",
"    ]. Clinical manifestations included AF during fetal life, neonatal sudden death, ventricular tachyarrhythmias, and waxing and waning cardiomyopathy. A genetic locus on chromosome 5p13 was linked to disease in this family.",
"   </p>",
"   <p>",
"    Chromosomal loci are large areas with multiple genes, and a specific genetic defect is not yet known for most loci. Examples of a monogenic cause of AF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 11p15.5 locus is associated with a gain-of-function mutation in the KVLQT1 (KCNQ1) gene, the protein product of which is the alpha-subunit of the slowly acting component of the outward-rectifying potassium current (IKs) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/81\">",
"       81",
"      </a>",
"      ]. This mutation is thought to initiate and maintain AF by reducing the action potential duration and effective refractory period in atrial myocytes.",
"     </li>",
"     <li>",
"      A different gain-of-function mutation in this gene has been associated with the congenital short QT syndrome, while loss-of function mutations are associated with long QT syndrome, type 1. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H9#H9\">",
"       \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Short QT syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H4#H4\">",
"       \"Genetics of congenital and acquired long QT syndrome\", section on 'LQT type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An autosomal dominant form of AF, usually in association with a dilated cardiomyopathy, has been associated with mutations in SCN5A, the cardiac sodium channel gene. In a report of individuals with SCN5A mutations, 27 percent had early features of dilated cardiomyopathy (mean age at diagnosis 20 years), 43 percent had atrial fibrillation (mean age at diagnosis 28 years), and 38 percent had dilated cardiomyopathy (mean age at diagnosis 48 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/83\">",
"       83",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations in SCN5A have also been identified in several other cardiac disorders, including the long QT syndrome, the Brugada syndrome, familial atrioventricular conduction block, and familial sick sinus syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638951744\">",
"    <span class=\"h2\">",
"     Birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible relationship between birth weight and the development of AF was evaluated in a prospective study of nearly 28,000 women over the age of 45 years, who were free of AF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/88\">",
"     88",
"    </a>",
"    ]. The age-adjusted hazard ratios (with &lt;2.5 kg [5.5 pounds] being the referent group) for incident AF increased significantly (1.0, 1.3, 1.28, 1.7, and 1.71) from the lowest to the highest birth weight category (&lt;2.5 [5.5], 2.5 [5.5] to 3.2 [7.1], 3.2 [7.1] to 3.9 [8.6], 3.9 [8.6] to 4.5, and &gt;4.5 [9.9] kg [pounds]), during a median follow-up of 14.5 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Inflammation and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory processes may play a role in the genesis of AF. Measurement of serum C-reactive protein (CRP), an acute phase reactant, has been used to assess the relationship between AF and inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link&amp;anchor=H18#H18\">",
"     \"C-reactive protein in cardiovascular disease\", section on 'Role in AF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies have reported elevated serum levels of CRP in patient populations with any of the following characteristics: later (after known high CRP) development AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/89\">",
"     89",
"    </a>",
"    ]; history of atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/90\">",
"     90",
"    </a>",
"    ]; failed cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/91\">",
"     91",
"    </a>",
"    ]; recurrence of AF after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/92\">",
"     92",
"    </a>",
"    ]; and development of AF after cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, inflammation is more likely a marker for other conditions associated with AF, as opposed to being a direct cause or a perpetuating agent. The strongest evidence against a direct causal role for inflammation, as detected by an elevation in CRP, comes from a Mendelian randomization study that evaluated nearly 47,000 individuals in two cohorts from Copenhagen, Demark [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11335?source=see_link\">",
"     \"Mendelian randomization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After multifactorial adjustment, a CRP level in the upper versus lower quintile was associated with a significantly increased risk of the development of AF (Hazard Ratio 1.77, 95% CI 1.22-2.55).",
"     </li>",
"     <li>",
"      Genotype combinations of four CRP polymorphisms were significantly associated with up to a 63 percent increase in plasma CRP levels, but not with an increased risk of the development of atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, inflammation, as determined by CRP, is not likely to be causative of atrial fibrillation.",
"   </p>",
"   <p>",
"    In addition to inflammation as detected by serum CRP, new onset AF and other acute cardiac events have been associated with pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link&amp;anchor=H19#H19\">",
"     \"Pneumococcal pneumonia in adults\", section on 'Acute cardiac events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H638951712\">",
"    <span class=\"h2\">",
"     Pericardial fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial fat is visceral adipose tissue with inflammatory properties; both obesity and inflammation are risk factors for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/95\">",
"     95",
"    </a>",
"    ]. In a study of 126 patients with AF and 76 controls, those with AF had a significantly higher pericardial fat volume (102 versus 76 ml) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/95\">",
"     95",
"    </a>",
"    ]. This was true for patients with either paroxysmal or persistent AF, and was independent of other traditional predictors of AF, including left atrial enlargement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic nervous system may be involved in the initiation and maintenance of AF. It may be particularly important in patients with paroxysmal AF, as both heightened vagal and sympathetic tone can promote AF. Vagal tone is predominant in normal hearts, which may explain why vagally-mediated AF is often seen in athletic young men without apparent heart disease who have slow heart rates during rest or sleep; such patients may also have an ECG pattern of typical atrial flutter alternating with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. In comparison, AF induced by increased sympathetic tone may be observed in patients with underlying heart disease or during exercise or other activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link&amp;anchor=H3#H3\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other supraventricular tachyarrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous transition between typical atrial flutter and AF has been observed, although little is known about the mechanism of this conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In addition, atrial fibrillation is, in some patients, associated with paroxysmal supraventricular tachycardia (PSVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. The most common causes of PSVT are atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia, which occurs in patients with the Wolff-Parkinson-White (WPW) syndrome or concealed accessory pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between AF and PSVT was illustrated in a report that evaluated 169 patients who presented with PSVT and were followed by clinic visits and transtelephonic ECG monitoring during symptomatic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/100\">",
"     100",
"    </a>",
"    ]. Nineteen percent had an episode of AF during a mean follow-up of 31 months. Neither the mechanism nor the rate of the PSVT was associated with the time to occurrence of AF.",
"   </p>",
"   <p>",
"    Enhanced vagal tone, as determined by baroreflex sensitivity, or an increase in dispersion of right atrial refractory periods may contribute to the development of AF associated with PSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/103\">",
"     103",
"    </a>",
"    ]. Alternatively, an atrial premature beat can cause stable PSVT to degenerate into AF.",
"   </p>",
"   <p>",
"    Among patients with WPW syndrome, the mechanism of AF may be retrograde conduction via the accessory pathway of a premature beat, stimulating the atrial myocardium during its vulnerable period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/104\">",
"     104",
"    </a>",
"    ]. Ablation of the accessory pathway reduces the incidence of subsequent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1688569\">",
"    <span class=\"h2\">",
"     Low serum magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing cardiac surgery, low serum magnesium is a risk predictor of the development of postoperative AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Risk factors'",
"    </a>",
"    .) In an observational study of over 3500 participants in the Framingham Offspring Study, individuals in the lower quartile of serum magnesium were approximately 50 percent more likely to develop AF compared with those in the upper quartiles after multivariable adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation occurs in up to 60 percent of binge drinkers with or without an underlying alcoholic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/107\">",
"     107",
"    </a>",
"    ]. Most cases occur during and following weekends or holidays when alcohol intake is increased, a phenomenon that has been termed \"the holiday heart syndrome.\" However, even modest amounts of alcohol can trigger AF in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link\">",
"     \"Alcoholic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Moderate, long-term alcohol consumption does not appear to be a risk factor for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/52,108,109\">",
"     52,108,109",
"    </a>",
"    ]. In an analysis of 4731 patients from the Framingham study, there was no significant association in either men or women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, heavy alcohol consumption is associated with an increased incidence of AF. Two large cohort studies found an increased incidence among men with heavy alcohol consumption (hazard ratio 1.45 in both) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Neither study found a correlation between heavy alcohol use and AF in women, but the ability to detect such a correlation was limited by the small numbers of women with alcohol consumption in this range. Another study of 1055 cases of AF occurring during long term follow up found an increased risk (relative risk 1.34, 95% CI 1.01-1.78) with consumption of more than 36 grams per day (approximately &gt;3",
"    <span class=\"nowrap\">",
"     drinks/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a widespread belief that caffeine, particularly at high doses, is associated with palpitations and a number of arrhythmias, including atrial fibrillation and supraventricular and ventricular ectopy. However, despite the theoretical relationship between caffeine and arrhythmogenesis, there is no evidence in humans that ingestion of caffeine in doses typically consumed can provoke AF or any other spontaneous arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38375?source=see_link&amp;anchor=H5#H5\">",
"     \"Cardiovascular effects of caffeine\", section on 'Arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fish and fish oil supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data has suggested that dietary fish intake or fish oil supplements, particularly those rich in long-chain n-3 fatty acids, may reduce the incidence of arrhythmias, although evidence is mixed with regard to both atrial and ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Fish intake and fish oil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to dietary fish intake and incident AF, three cohort studies (approximately 45,000, 48,000, and 5000 individuals) found no relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/112-114\">",
"     112-114",
"    </a>",
"    ], while one (approximately 5000 individuals) suggested a reduction in AF burden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications can cause or contribute to the development of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/116\">",
"     116",
"    </a>",
"    ]. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/117\">",
"     117",
"    </a>",
"    ], adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/118\">",
"     118",
"    </a>",
"    ], and, since increased vagal tone can induce AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/97\">",
"     97",
"    </a>",
"    ], drugs that enhance vagal tone, such as digitalis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Autonomic dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravenous adenosine is used to terminate supraventricular arrhythmias. In a report of 200 consecutive patients presenting with paroxysmal supraventricular tachycardia, the administration of 12 mg of adenosine via the femoral vein terminated the arrhythmia in 99 percent, but AF or AF and atrial flutter occurred in 24 patients (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/118\">",
"     118",
"    </a>",
"    ]. AF has also been noted after adenosine use in patients with the Wolff-Parkinson-White syndrome, a proarrhythmic effect that may lead to very rapid ventricular rates due to conduction down the accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ) are widely used in the treatment of osteoporosis, and concern has been raised that these drugs can cause AF. The weight of evidence suggests that the risk of AF from oral bisphosphonates is small, if it exists at all. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H49#H49\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case-control studies have suggested a modest increased risk for the development of AF in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. However, the absence of an accepted biologic mechanism and the susceptibility of case-control studies to unmeasured confounders, makes us cautious about the strength of this association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/54/28522/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence and prevalence of atrial fibrillation (AF) depends upon the population studied and the intensity of monitoring. Both increase significantly with increasing age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypertensive heart disease and coronary heart disease are the most common underlying disorders in patients with AF in developed countries. Other frequent causes include alcohol excess, heart failure, valvular heart disease including both regurgitant and stenotic lesions, and hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rheumatic heart disease, although now uncommon in developed countries, is associated with a high incidence of AF. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial fibrillation occurs in relation to a variety of different types of surgery; the incidence is greatest in patients undergoing coronary artery bypass graft or cardiac valve surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic, heavy alcohol use does increase the risk of AF in men, while the impact of heavy alcohol use in women is less clear. Chronic moderate alcohol use does not appear to increase the incidence of AF in men or women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The heritability of AF is complex. For the majority of patients, genetic susceptibility, if present, is probably a polygenic phenomenon, meaning that it is due to the combined effects of a number of genes. (See",
"      <a class=\"local\" href=\"#H262710391\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with structurally normal hearts or mild hypertensive heart disease, AF appears to be \"triggered\" by PACs, most commonly from the pulmonary venous ostia.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/1\">",
"      Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/2\">",
"      Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/3\">",
"      Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001; 86:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/4\">",
"      Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/5\">",
"      Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/6\">",
"      HISS RG, LAMB LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962; 25:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/7\">",
"      Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/8\">",
"      Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/9\">",
"      Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/10\">",
"      Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008; 71:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/11\">",
"      Jabaudon D, Sztajzel J, Sievert K, et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/12\">",
"      Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/13\">",
"      Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/14\">",
"      Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/15\">",
"      Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/16\">",
"      Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/17\">",
"      Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med 2010; 170:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/18\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/19\">",
"      Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994; 89:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/20\">",
"      Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/21\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/22\">",
"      Kolb C, N&uuml;rnberger S, Ndrepepa G, et al. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am J Cardiol 2001; 88:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/23\">",
"      Liberthson RR, Salisbury KW, Hutter AM Jr, DeSanctis RW. Atrial tachyarrhythmias in acute myocardial infarction. Am J Med 1976; 60:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/24\">",
"      Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/25\">",
"      Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000; 140:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/26\">",
"      Eldar M, Canetti M, Rotstein Z, et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/27\">",
"      Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/28\">",
"      Kramer RJ, Zeldis SM, Hamby RI. Atrial fibrillation--a marker for abnormal left ventricular function in coronary heart disease. Br Heart J 1982; 47:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/29\">",
"      Zimetbaum PJ, Josephson ME, McDonald MJ, et al. Incidence and predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 2000; 36:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/30\">",
"      Friedman HZ, Weber-Bornstein N, Deboe SF, Mancini GB. Cardiac care unit admission criteria for suspected acute myocardial infarction in new-onset atrial fibrillation. Am J Cardiol 1987; 59:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/31\">",
"      Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol 2002; 40:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/32\">",
"      Probst P, Goldschlager N, Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. Circulation 1973; 48:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/33\">",
"      Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol 1996; 77:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/34\">",
"      Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970; 32:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/35\">",
"      Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/36\">",
"      Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/37\">",
"      Tikoff G, Schmidt AM, Hecht HH. Atrial fibrillation in atrial septal defect. Arch Intern Med 1968; 121:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/38\">",
"      Berger F, Vogel M, Kramer A, et al. Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Ann Thorac Surg 1999; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/39\">",
"      Weber DM, Phillips JH Jr. A re-evaluation of electrocardiographic changes accompanying acute pulmonary embolism. Am J Med Sci 1966; 251:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/40\">",
"      Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/41\">",
"      Davidson E, Weinberger I, Rotenberg Z, et al. Atrial fibrillation. Cause and time of onset. Arch Intern Med 1989; 149:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/42\">",
"      Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/43\">",
"      WALSH JJ, BURCH GE, BLACK WC, et al. IDIOPATHIC MYOCARDIOPATHY OF THE PUERPERIUM (POSTPARTAL HEART DISEASE). Circulation 1965; 32:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/44\">",
"      Ansari A, Larson PH, Bates HD. Cardiovascular manifestations of systemic lupus erythematosus: current perspective. Prog Cardiovasc Dis 1985; 27:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/45\">",
"      Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA 1976; 235:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/46\">",
"      Levine HD. Myocardial fibrosis in constrictive pericarditis. Electrocardiographic and pathologic observations. Circulation 1973; 48:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/47\">",
"      Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003; 107:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/48\">",
"      Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/49\">",
"      Mooe T, Gullsby S, Rabben T, Eriksson P. Sleep-disordered breathing: a novel predictor of atrial fibrillation after coronary artery bypass surgery. Coron Artery Dis 1996; 7:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/50\">",
"      Schulz R, Eisele HJ, Seeger W. Nocturnal atrial fibrillation in a patient with obstructive sleep apnoea. Thorax 2005; 60:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/51\">",
"      Munger TM, Dong YX, Masaki M, et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. J Am Coll Cardiol 2012; 60:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/52\">",
"      Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/53\">",
"      Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000; 101:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/54\">",
"      Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008; 117:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/55\">",
"      Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/56\">",
"      Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/57\">",
"      Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/58\">",
"      Arnsdorf MF, Childers RW. Atrial electrophysiology in experimental hyperthyroidism in rabbits. Circ Res 1970; 26:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/59\">",
"      Chen YC, Chen SA, Chen YJ, et al. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol 2002; 39:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/60\">",
"      Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/61\">",
"      Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001; 142:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/62\">",
"      Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med 1996; 156:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/63\">",
"      Wong PS, Hee FL, Lip GY. Atrial fibrillation and the thyroid. Heart 1997; 78:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/64\">",
"      Barnes DJ, O'Connor JD, Bending JJ. Hypothyroidism in the elderly: clinical assessment versus routine screening. Br J Clin Pract 1993; 47:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/65\">",
"      Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009; 158:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/66\">",
"      Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/67\">",
"      Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/68\">",
"      Pires LA, Wagshal AB, Lancey R, Huang SK. Arrhythmias and conduction disturbances after coronary artery bypass graft surgery: epidemiology, management, and prognosis. Am Heart J 1995; 129:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/69\">",
"      Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987; 94:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/70\">",
"      Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/71\">",
"      Asher CR, Miller DP, Grimm RA, et al. Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Am J Cardiol 1998; 82:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/72\">",
"      Pavri BB, O'Nunain SS, Newell JB, et al. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. J Am Coll Cardiol 1995; 25:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/73\">",
"      Ahmari SA, Bunch TJ, Chandra A, et al. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. J Heart Lung Transplant 2006; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/74\">",
"      Polanczyk CA, Goldman L, Marcantonio ER, et al. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med 1998; 129:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/75\">",
"      Vaporciyan AA, Correa AM, Rice DC, et al. Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg 2004; 127:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/76\">",
"      Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004; 291:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/77\">",
"      Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 2010; 304:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/78\">",
"      Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 2003; 41:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/79\">",
"      Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006; 27:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/80\">",
"      Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/81\">",
"      Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/82\">",
"      Ellinor PT, Shin JT, Moore RK, et al. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 2003; 107:2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/83\">",
"      Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005; 293:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/84\">",
"      Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/85\">",
"      Lubitz SA, Sinner MF, Lunetta KL, et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation 2010; 122:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/86\">",
"      Ritchie MD, Rowan S, Kucera G, et al. Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol 2012; 60:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/87\">",
"      Oberti C, Wang L, Li L, et al. Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy. Circulation 2004; 110:3753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/88\">",
"      Conen D, Tedrow UB, Cook NR, et al. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 2010; 122:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/89\">",
"      Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/90\">",
"      Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/91\">",
"      Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/92\">",
"      Malouf JF, Kanagala R, Al Atawi FO, et al. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005; 46:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/93\">",
"      Marott SC, Nordestgaard BG, Zacho J, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010; 56:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/94\">",
"      Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/95\">",
"      Al Chekakie MO, Welles CC, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010; 56:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/96\">",
"      Herweg B, Dalal P, Nagy B, Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 1998; 82:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/97\">",
"      Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/98\">",
"      Ortiz J, Niwano S, Abe H, et al. Mapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. Circ Res 1994; 74:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/99\">",
"      Hsieh MH, Tai CT, Tsai CF, et al. Mechanism of spontaneous transition from typical atrial flutter to atrial fibrillation: role of ectopic atrial fibrillation foci. Pacing Clin Electrophysiol 2001; 24:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/100\">",
"      Hamer ME, Wilkinson WE, Clair WK, et al. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1995; 25:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/101\">",
"      Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/102\">",
"      Bauernfeind RA, Wyndham CR, Swiryn SP, et al. Paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1981; 47:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/103\">",
"      Chen YJ, Chen SA, Tai CT, et al. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 1998; 32:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/104\">",
"      Haissaguerre M, Fischer B, Labb&eacute; T, et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992; 69:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/105\">",
"      Waspe LE, Brodman R, Kim SG, Fisher JD. Susceptibility to atrial fibrillation and ventricular tachyarrhythmia in the Wolff-Parkinson-White syndrome: role of the accessory pathway. Am Heart J 1986; 112:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/106\">",
"      Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013; 127:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/107\">",
"      Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the \"Holiday Heart\": alcohol-associated cardiac rhythm disorders. Am Heart J 1978; 95:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/108\">",
"      Mukamal KJ, Psaty BM, Rautaharju PM, et al. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. Am Heart J 2007; 153:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/109\">",
"      Djouss&eacute; L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004; 93:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/110\">",
"      Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004; 164:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/111\">",
"      Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005; 112:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/112\">",
"      Berry JD, Prineas RJ, van Horn L, et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010; 105:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/113\">",
"      Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/114\">",
"      Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006; 151:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/115\">",
"      Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/116\">",
"      van der Hooft CS, Heeringa J, van Herpen G, et al. Drug-induced atrial fibrillation. J Am Coll Cardiol 2004; 44:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/117\">",
"      Varriale P, Ramaprasad S. Aminophylline induced atrial fibrillation. Pacing Clin Electrophysiol 1993; 16:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/118\">",
"      Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997; 127:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/119\">",
"      Exner DV, Muzyka T, Gillis AM. Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine. Ann Intern Med 1995; 122:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/120\">",
"      Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011; 343:d3450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/121\">",
"      De Caterina R, Ruig&oacute;mez A, Rodr&iacute;guez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med 2010; 170:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/54/28522/abstract/122\">",
"      Gurwitz JH. NSAIDs and atrial fibrillation. BMJ 2011; 343:d2495.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1004 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28522=[""].join("\n");
var outline_f27_54_28522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H102126448\">",
"      - Subclinical AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK PREDICTION MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LONE AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypertensive heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - AF as a presentation of ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other types of cardiopulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177150160\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H118325398\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262710213\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262710391\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262710418\">",
"      - Polygenic inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262710425\">",
"      - Monogenic inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638951744\">",
"      Birth weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Inflammation and infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H638951712\">",
"      Pericardial fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other supraventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1688569\">",
"      Low serum magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fish and fish oil supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1004|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34098\" title=\"figure 1\">",
"      Prevalence of atrial fibrillation by sex and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/14/2286\" title=\"figure 2\">",
"      Prevalence of atrial fibrillation with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/61/22493\" title=\"figure 3\">",
"      Incidence of AF with age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38375?source=related_link\">",
"      Cardiovascular effects of caffeine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39721?source=related_link\">",
"      Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11335?source=related_link\">",
"      Mendelian randomization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_54_28523="DSM-IV-TR criteria for substance abuse";
var content_f27_54_28523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F74334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F74334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR criteria for substance abuse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        A. A maladaptive pattern of substance use leading to clinically significant impairment or distress, as manifested by one (or more) of the following, occurring within a 12-month period:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (eg, repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; neglect of children or household)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent substance use in situations in which it is physically hazardous (eg, driving an automobile or operating a machine when impaired by substance use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent substance-related legal problems (eg, arrests for substance-related disorderly conduct)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (eg, arguments with spouse about consequences of intoxication, physical fights)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B. The symptoms have never met the criteria for Substance Dependence for this class of substance.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright &copy; 2000 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28523=[""].join("\n");
var outline_f27_54_28523=null;
var title_f27_54_28524="Description of genital ulcer II";
var content_f27_54_28524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of sexually transmitted genital ulcers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary syphilis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genital herpes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chancroid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lymphogranuloma venereum",
"       </td>",
"       <td class=\"subtitle1\">",
"        Donovanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        Painless; may become tender if secondarily infected.",
"       </td>",
"       <td>",
"        Common; more prominent with initial infection than with recurrences.",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inguinal lymphadenopathy",
"       </td>",
"       <td>",
"        Unilateral or bilateral; firm, movable, and nontender; do not suppurate.",
"       </td>",
"       <td>",
"        Usually bilateral, firm, and tender; more common in primary episodes than in recurrences.",
"       </td>",
"       <td>",
"        Unilateral (rarely bilateral); overlying erythema; matted, fixed, and tender; may suppurate.",
"       </td>",
"       <td>",
"        Unilateral or bilateral; initially movable, firm, and tender; later indolent; fixed and matted; \"sign of Groove\" may suppurate; fistulas.",
"       </td>",
"       <td>",
"        Pseudobuboes; subcutaneous perilymphatic granulamotous lesions that produce inguinal swelling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional symptoms",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Common in primary episode; less likely in recurrences.",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Frequent",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Course of disease if untreated",
"       </td>",
"       <td>",
"        Slowly resolves to latency (2 - 6 weeks).",
"       </td>",
"       <td>",
"        Typically recurs.",
"       </td>",
"       <td>",
"        May progress to erosive lesions.",
"       </td>",
"       <td>",
"        Local lesions heal; systemic disease may progress; disfigurement; late complications.",
"       </td>",
"       <td>",
"        Worsens slowly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic tests",
"       </td>",
"       <td>",
"        Darkfield exam, direct immunofluorescence, FTA-ABS, VDRL.",
"       </td>",
"       <td>",
"        Tzanck smear, culture, Pap smear, direct immunofluorescence, electron-microscopy, direct immunoperoxidase staining, serology.",
"       </td>",
"       <td>",
"        Culture, biopsy (rarely done); Gram stained smears have low specificity.",
"       </td>",
"       <td>",
"        Lymphogranuloma venereum (LGV) complement fixation test; isolation of the microorganism by culture.",
"       </td>",
"       <td>",
"        \"Donovan bodies\" in tissue smears; biopsy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Martin DH, Mroczkowski TF: Sexually Transmitted Diseases. In: The Skin and Infection: A Color Atlas and Text. C. V. Sanders and LT Nesbitt, eds. Baltimore, Maryland: Williams &amp; Wilkins, 1995, p. 95.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28524=[""].join("\n");
var outline_f27_54_28524=null;
var title_f27_54_28525="Common causes of syncope";
var content_f27_54_28525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67409%7ECARD%2F76776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67409%7ECARD%2F76776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reflex mechanisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasovagal and vasodepressor syncope (neurocardiogenic syncope)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Micturition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deglutition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Orthostatic hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dysautonomias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluid depletion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Illness, bedrest, deconditioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs - antidepressants, sympathetic blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hysterical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Panic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anxiety disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undiagnosed seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improperly diagnosed syncope - confusional states, eg, due to hypoglycemia, stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced loss of consciousness (consider alcohol, illicit drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        AV block with bradycardia (structural changes, drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sinus pauses/bradycardia (vagal causes, sick sinus syndrome, negative chronotropic drugs such as beta blockers and calcium channel blockers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ventricular tachycardia due to structural heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonarrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syncope of unknown origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        About 50 percent of patients presenting to the hospital",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major uncommon causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Supraventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long QT interval syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myocardial infarction causing bradycardias and tachycardias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right ventricular dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonarrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary embolus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dissecting aortic aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subclavian steal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Glossopharyngeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postprandial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carotid sinus hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multivessel obstructive cerebrovascular disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28525=[""].join("\n");
var outline_f27_54_28525=null;
var title_f27_54_28526="Abnormal larynx examples";
var content_f27_54_28526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal larynx examples",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Photograph shows grade 1+ vocal fold edema. B) Grade 2+ vocal fold edema virtually always represents pseudosulcus vocalis. C) Pseudosulcus vocalis is seen on the right and some sessile changes on the left. The sessile changes are characteristic of grade 3+ vocal fold edema. D) Polypoid degeneration is graded as 4+ vocal fold edema. All four of these views also show partial or complete ventricular obliteration and various degrees of posterior commissure hypertrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Belafsky, P, Postma, G, Amin, M, Koufman, J. Symptoms and findings of laryngopharyngeal reflux. Ear Nose Throat J 2002; 81(9 Suppl 2):10. Copyright &copy; 2002 Ear, Nose, and Throat Journal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28526=[""].join("\n");
var outline_f27_54_28526=null;
var title_f27_54_28527="Platelet G proteins";
var content_f27_54_28527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    G-protein coupled platelet receptors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 433px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the function of G-protein coupled platelet receptors. Upon stimulation of the receptor by the appropriate agonist (top left), there is a dissociation of the associated heterotrimeric G-protein into a GTP-binding alpha subunit and a beta-gamma heterodimeric subunit, each of which is then free to stimulate those enzymes that produce second messengers within the platelet. As examples, the G alpha-subclass 12/13 subunit induces platelet shape change, the G alpha-subclass s and the G alpha-subclass i subunits stimulate or inhibit adenyl cyclase activity, respectively, and the G alpha-subclass q subunit activates phospholipase C beta (PLC). The separated G beta-gamma subunit also activates PLC beta as well as phosphatidylinositol 3-kinase (PI3K).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_54_28527=[""].join("\n");
var outline_f27_54_28527=null;
